Stockwinners Market Radar for January 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:13 EST Cathie Wood's ARK Investment bought 169.5K shares of Teladoc on Monday

20:09 EST Cathie Wood's ARK Investment bought 143.5K shares of Coinbase on Monday

19:58 EST Syros Pharmaceuticals updates on clinical development program - Earlier today, the company's CEO Nancy Simonian stated: ""2022 promises to be a transformative year as we continue to advance our studies of tamibarotene, SY-2101, and SY-5609. We are looking forward to three clinical data readouts this year as well as pivotal data from the SELECT-MDS-1 trial in late 2023 or early 2024. Additionally, in the second half of this year we expect to nominate our new development candidate from our CDK12 program, highlighting the productivity of our gene control discovery engine and our expertise in CDK inhibition. Together, we believe these upcoming milestones will provide insight into the clinical potential of our development-stage assets and lay the foundation for our long-term growth as we advance Syros into a fully integrated biopharmaceutical company. We are pleased with our recent interactions with the U.S. Food and Drug Administration on the Phase 3 clinical trial design of SY-2101, which we now expect to initiate in the first quarter of 2023. In addition, based on preclinical data that supports CDK7 inhibition's potential across a range of hematologic malignancies, we expect to start in the second half of this year a Phase 1 single agent study of SY-5609 in patients with relapsed blood cancers, including B-cell lymphomas, prior to moving into specific indications. We are excited to be the first company to advance a CDK7 inhibitor into hematology clinical development. The trial results have potential to benefit a broader patient population as well as demonstrate CDK7 inhibition as a novel approach for many difficult-to-treat hematologic cancers." The company also indicated that "based on its current operating plans, Syros expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2023."

18:52 EST Burcon NutraScience CEO Johann Tergesen to step down - Burcon NutraScience announced that Johann Tergesen will be stepping down as President and CEO. Mr. Tergesen will remain CEO until either a successor is appointed by the Company's board of directors, or no later than February 28, 2022. To ensure an orderly transition, he will continue in an ongoing capacity as an advisor to the company and Burcon's board of directors. The company has engaged Kincannon & Reed, an executive search firm specialising in the food and agribusiness sectors, to assist in recruiting a new CEO.

18:19 EST Four Corners Property Trust acquires VCA Animal Hospital property for $1.7M - Four Corners Property Trust announced the acquisition of a VCA Animal Hospital property for $1.7M. The property is located in a highly trafficked corridor in Michigan and is corporate-operated under a net lease with approximately 7 years of term remaining. The transaction was priced at a 7.0% going-in cash capitalization rate, exclusive of transaction costs.

17:39 EST Rivian Automotive drops after WSJ reports COO left in December - Rivian dropped over $4.00 per share or approximately 5%, to around $77.20 per share, in after-hours trading on Monday, after the Wall Street Journal reported the company's chief operating officer, Rod Copes, had retired from the company in December.

17:25 EST Pfizer awarded $442.13M Army contract modification for Paxlovid - Pfizer was awarded a $442.13M modification to a contract to produce 835,000 Paxlovid oral antiviral therapeutic treatments for administration, vendor-managed inventory and distribution activities. Work will be performed in New York, New York, with an estimated completion date of March 31, 2023. Fiscal 2022 research, development, test and evaluation, Army funds in the amount of $442.13M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:21 EST NewAge CEO Brent Willis to resign, effective immediately - On January 10, NewAge filed a Form 8-K with the U.S. SEC announcing that the NewAge Board of Directors and the CEO, Brent Willis, have agreed that Willis will resign as CEO, Director, and employee, effective immediately.

17:02 EST Greenbrook TMS COO Roerto Drassinover steps down - Greenbrook TMS Inc. announced that Roberto Drassinower will be stepping down from his role as Chief Operating Officer of the company, effective immediately, but will continue to provide advisory services to the company pursuant to the terms of a consulting agreement with the company. Drassinower commented: "I am excited to continue supporting Greenbrook and Bill Leonard in our growth strategy for the business while being able to take time to spend with my family."

17:01 EST Osisko Gold earns roughly 19,830 attributable gold equivalent ounces in Q4 - Osisko Gold Royalties Ltd provided an update on its fourth quarter 2021 deliveries, sales and cash margins, as well as a recap of certain asset advancements over the course of 2021 that will continue to provide meaningful catalysts in 2022. Osisko earned approximately 19,830 attributable gold equivalent ounces in the fourth quarter of 2021, for a total of approximately 80,000 GEOs in 2021, in line with its annual guidance of 78,000 - 82,000 GEOs. These figures exclude 3,042 GEOs earned in the fourth quarter (and 9,210 GEOs earned in 2021) from the Renard diamond stream. Osisko recorded preliminary revenues of C$50.7 million during the fourth quarter and preliminary cost of sales (excluding depletion) of C$3.7 million resulting in a cash margin of approximately C$47.0 million, a quarterly record from the royalty and stream interests. Osisko's cash margin was approximately 93% during the fourth quarter of 2021 (97% excluding the Renard diamond stream).

16:51 EST Brookdale Senior Living reports December-end occupancy 74.5% - Brookdale Senior Living reported its consolidated occupancy for December 2021 at 74.5% vs. 74.3% in November, stating: "December was the 10th consecutive month of weighted average occupancy growth and it was also the first December since 2012 to deliver sequential occupancy growth. Fourth quarter weighted average occupancy increased 100 bps, compared to third quarter."

16:35 EST STAG Industrial announces CEO succession plan, new CFO - STAG Industrial announced that pursuant to ongoing management succession planning by the board, the company expects that on July 1, Benjamin Butcher, the company's current chairman and CEO, will become executive chairman and that William Crooker, the company's current president, will be appointed CEO and join the board. The company further announced that its board appointed Matts Pinard to the role of executive VP, CFO and Treasurer. Crooker, the company's CFO and Treasurer until Pinard's appointment, will continue in his role as president until assuming additional duties in July pursuant to the succession plan.

16:33 EST Allogene Therapeutics says FDA lifts hold on clinical trials - Cellectis (CLLS) stated that its licensed partner, Allogene Therapeutics (ALLO) announced that the U.S. FDA has lifted the hold on its clinical trials. The FDA had placed a clinical hold on all five of Allogene's clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogene's ALPHA2 study. Allogene reported that the investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogene's manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T product or in any other patient treated with the same ALLO-501A lot. The abnormality occurred in the patient after the cell product was administered. It involved regions of the T cell receptor and immunoglobulin genes known to undergo rearrangement as part of the natural T cell or B cell maturation process. Allogene also announced that following the lift of the clinical holds and pending final discussions with the FDA, Allogene intends to initiate a Phase 2 pivotal trial of ALLO-501A in relapsed/refractory large B-cell lymphoma mid-year 2022. Allogene's allogeneic CAR-T programs utilize Cellectis' technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. Allogene has an exclusive license to Cellectis' technologies for ALLO-715, ALLO-605 (both directed at BCMA) and ALLO-316 (directed at CD70) and holds development and commercial rights for these investigational product candidates.

16:32 EST TechnipFMC announces sale of stake in Technip Energies - TechnipFMC plc announced the sale of 9M Technip Energies N.V. shares through private sale transactions. The sale price of the Shares in the Sale is set at EUR 13.15 per Share, yielding total gross proceeds of EUR 118.4M. Upon completion of the Sale, representing approximately 5% of Technip Energies' issued and outstanding share capital, TechnipFMC retains a direct stake of approximately 7% of Technip Energies' share capital.

16:27 EST Intel jumps 5% to $58.15 after naming new CFO

16:23 EST Ellington Financial makes equity investment in Sheridan Capital - Sheridan Capital and Ellington Financial jointly announced a strategic partnership whereby EFC made an equity investment in Sheridan Capital, a player in originating commercial real estate bridge loans. "We believe that cementing our partnership with EFC will allow us to continue to provide unique and creative loan products to the market," said Aaron Kurlansky, Principal of Sheridan Capital. "In a competitive sector, we differentiate ourselves by streamlining the loan process and providing dependable products for virtually all asset classes and loan sizes." Laurence Penn, Chief Executive Officer and President of Ellington Financial, added, "We have been investing with the principals of Sheridan Capital for more than a decade. Over that wide range of market environments, Sheridan has continued to provide us with a steady stream of attractive commercial real estate debt investments, all while scaling its business. Meanwhile, Sheridan has built an outstanding reputation as offering efficient and flexible financing solutions to commercial real estate owners. With this strategic partnership, I look forward to continuing to grow the business together."

16:19 EST TechnipFMC announces voluntary delisting from Euronext Paris - TechnipFMC announced that following a comprehensive review of its strategic objectives, it is proceeding with the voluntary delisting of its shares from Euronext Paris. Following the partial spin-off of Technip Energies and the progressive selldown of the company's remaining ownership stake, the Company has refocused as a pure-play technology and services provider to the traditional and new energies industries. It now has its principal place of business in Houston. These actions have led the Board of Directors to conclude that a single listing on the New York Stock Exchange is more consistent with the company's strategic refocus and shareholder base, and allows the company to better align with its most appropriate peer set. In addition, the company expects that the savings in costs, administrative requirements, and managerial time required to maintain a dual listing can be redirected to other initiatives that contribute to shareholder value. The delisting has been approved by the Board of Directors of Euronext Paris SA and the company's shares will remain listed on the NYSE under the symbol "FTI".

16:19 EST Targa Resources to repurchase interests in development company JV for $925M - Targa Resources announced that it has executed agreements to repurchase interests in its development company joint ventures from investment vehicles affiliated with Stonepeak for approximately $925M. Targa had approximately $3.2B of available liquidity at December 31, 2021 and intends to fund the DevCo acquisition using available liquidity. The acquisition will close on January 14, 2022. Pro forma, Targa will own a 75% interest in its Grand Prix NGL Pipeline, 100% of its Train 6 fractionator in Mont Belvieu, TX, and a 25% equity interest in the Gulf Coast Express Pipeline. Targa will benefit from a full year of Adjusted EBITDA and cash flows associated with the acquired DevCo JV assets in 2022.

16:18 EST Micron CFO David Zinsner resigns, Sumit Sadana named interim CFO - Micron (MU) announced that David Zinsner, executive vice president and CFO, has resigned from the company. Zinsner started at Micron in February 2018 and is departing to join Intel (INTC) as its CFO. A formal search for a new CFO has actively commenced. Micron has appointed Executive Vice President and Chief Business Officer Sumit Sadana to the additional role of interim CFO with immediate effect through the transition period. Micron's financial guidance for the second quarter of fiscal 2022 remains unchanged.

16:17 EST Duluth Holdings reports Holiday period sales up 6.4% y/y - Duluth Holdings announced net sales results for the nine-week period from November 1, 2021 through January 2, 2022. Net sales increased 6.4% to $224.3 million compared to $210.9 million in the 2020 Holiday Period and increased 5.4% when compared to the same period in 2019. Retail net sales increased $21.7 million, or 37.8%, to $79.0 million compared to $57.3 million in the 2020 Holiday Period nd decreased 4.5% when compared to the same period in 2019. Direct net sales decreased 5.4% to $145.3 million compared to $153.5 million in the 2020 Holiday Period and increased 11.7% when compared to the same period in 2019. President and CEO, Sam Sato commented, "Our Holiday Period results reflect strength in our product offering, marketing effectiveness and customer demand despite facing continued supply chain headwinds. Our Holiday Period sales growth of 6.4% was achieved with excellent gross margin performance and we are pleased to reaffirm our fiscal 2021 outlook."

16:16 EST KKR names Ryan Stork as COO - KKR & Co. (KKR) announced that Ryan Stork has joined KKR as a Partner and COO. Stork is joining KKR from BlackRock (BLK) where he held multiple leadership roles for more than 20 years, including most recently as Deputy COO.

16:11 EST Golub Capital announces $867.7M in new middle-market originations in Q1 - Golub Capital announced that it originated $867.7M in new middle-market investment commitments during the three months ended December 31, 2021. Approximately 88% of the new middle-market investment commitments were one stop loans, 4% were senior secured loans and 8% were equity and other securities. Of the new middle-market investment commitments, $765.7M funded at close. Total investments at fair value are estimated to have increased by approximately 5.1%, or $251.9M, during the three months ended December 31, 2021 after factoring in debt repayments, sales of securities, net fundings on revolvers and net change in unrealized gains (losses).

16:08 EST Allegro MicroSystems announces CFO Walsh to retire, Derek D'Antilio succeeds - Allegro MicroSystems announced that Paul Walsh, current Senior Vice President Chief Financial Officer, CFO, and Treasurer, will be retiring. He will be succeeded by Derek D'Antilio, who was selected after an extensive search and will be joining the Allegro management team effective January 10. Mr. Walsh will remain in an advisory capacity until February 4, to ensure a smooth and orderly transition of responsibilities. Mr. D'Antilio will report to Ravi Vig, President and Chief Executive Officer, and will oversee the company's global finance team. He joins Allegro with more than 20 years of financial and operating experience in semiconductor and high technology companies and is an accomplished CFO who brings a broad range of financial experience, including a background with global public companies in corporate finance, strategic planning, M&A, capital raising efforts and investor relations.

16:07 EST Limoneira sees fresh lemon volumes 4.5M-5M cartons for FY22 - The COVID-19 pandemic continues to affect the Company's food service business and industry logistics on a global basis. The Company believes it will experience improving results in fiscal year 2022 compared to fiscal year 2021 due to its stronger position in retail food and club grocery and growing brokered fruit revenues. As food service and export markets recover, the Company expects lemon prices to increase in fiscal year 2022 compared to fiscal year 2021. The Company expects fresh lemon volumes to be in the range of 4.5 million to 5.0 million cartons for fiscal year 2022. Avocado volumes are expected to be in the range of 5.0 million to 6.0 million pounds for fiscal year 2022. The Company expects to receive $80 million from Harvest at Limoneira during the next five fiscal years, beginning in fiscal year 2022.

16:06 EST BioAtla, Bristol-Myers announce clinical collaboration - BioAtla (BCAB) announced that it has entered into a clinical collaboration with Bristol Myers Squibb (BMY) to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo. Under the terms of the agreement, BioAtla and Bristol Myers Squibb will collaborate on clinical trials of separate combination therapies using two of BioAtla's Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdvio. BioAtla will serve as the study sponsor and will be responsible for costs associated with the trial execution. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study.

16:03 EST Amgen, BioLabs LA: Karma Biotechnologies receives second Amgen Golden Ticket - Amgen and BioLabs LA at the Lundquist Institute announced that Karma Biotechnologies has been awarded the second Amgen Golden Ticket in Southern California. Karma Biotechnologies will receive one year of lab space at BioLabs LA at the Lundquist Institute as well as additional facility benefits and connections to Amgen's scientific and business leaders.

16:01 EST Medtronic: Micra AV Transcatheter Pacing System approved in Japan - Medtronic announced it has received approval from Japan's Ministry of Health, Labor and Welfare for the sale and reimbursement of the Micra AV Transcatheter Pacing System, and the company will launch the product this month. This approval expands the number of patients in Japan - one of the largest markets in the world - who are eligible to receive the Micra TPS, the world's smallest pacemaker. The Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical signals between the chambers of the heart are impaired. The Micra TPS is the first-ever leadless pacemaker; its first version was approved in Japan in 2017 for patients who only require single-chamber pacing.

14:54 EST 10X Genomics saw headwinds to business in December from omicron surge - Says saw typical year-end budget flush within biopharma. Says was less impacted overall by omicron, which was offset by some cases of budget extension into 2022. Says doesn't see a budget flush so much from the academic customers given the impact of omicron. Says saw headwinds to business in December from omicron surge, resulting from decreased activity in Northeast region, particular with academic customers. Says case counts are "still high" in January. Says gets to see a meaningful change from the situation in December. Says still seeing risks with supply chain related to global logistics and the sourcing of key components. Comments taken from JPMorgan Healthcare conference.

13:51 EST Airbus signs purchase deal with Azorra for 22 A220 aircraft - Airbus said it has signed a purchase agreement with Azorra for twenty-two A220 Family aircraft including twenty A220-300s and two ACJ TwoTwenty aircraft. Azorra is a Fort Lauderdale, Florida, USA, based aircraft lessor focused on executive, regional and mid-size aircraft. Azorra's purchase is the latest endorsement for the A220 Family aircraft and reaffirms the strong market demand for Airbus' newest single-aisle aircraft. "The A220 is ideally suited for Azorra's growing portfolio. We are excited to partner with Airbus on this popular, next generation aircraft. We look forward to offering its superior economics and environmental efficiency to our customers," said John Evans, CEO of Azorra. "We are also thrilled with the opportunity to expand Azorra's executive jet leasing business with the new ACJ TwoTwenty. Azorra's new partnership with Airbus and unique ability to offer fleet transition solutions for airlines and executive jet leases to business aviation customers are key differentiators that bring significant value to our customers."

13:50 EST Airbus delivered 611 commercial aircraft in 2021

13:26 EST Sysco CEO: Omicron has 'zero' impact on long-term agenda

13:25 EST Sysco 'noticing,' 'experiencing' impact from omicron, says CEO Hourican - Comments taken from the ICR Conference 2022.

13:01 EST MKS Instruments withdraws from Photonics West 2022 - MKS Instruments announced that it has withdrawn from exhibiting at Photonics West 2022 in San Francisco. "The health and safety of our employees and customers is our top priority, and given the rapid rise in COVID-19 cases, we have made the difficult decision to withdraw from exhibiting at Photonics West 2022," said John Lee, President and CEO of MKS. "We want to extend our thanks to the SPIE team for their work during these uncertain times, and we look forward to returning in 2023."

12:49 EST AXT Inc. announces formal application for subsidiary IPO on STAR Market - AXT, Inc. announced that its wafer manufacturing subsidiary in China, Beijing Tongmei Xtal Technology Co., Ltd., or "Tongmei," has submitted to the Shanghai Stock Exchange, and the Shanghai Stock Exchange has accepted for review, a formal application to list Tongmei's shares in an initial public offering on the Shanghai Stock Exchange's Sci-Tech innovAtion boaRd, otherwise known as the "STAR Market." The company said: "The process of going public on the STAR Market includes several periods of review and, therefore, is a lengthy process. Tongmei does not expect to complete the IPO until the second half of 2022. The process of going public on the STAR Market is complicated and we have little or no experience in taking a company public in China. There can be no assurance that this process will be completed. The listing of Tongmei on the STAR Market will not change the status of AXT as a U.S. public company." "This is a significant achievement and an important milestone for AXT. We founded Tongmei back in 1998. Since then, it has grown into a company that is engaged in the research, development, production and sale of InP substrates, GaAs substrates, germanium substrates, PBN and other high-purity materials, which we believe makes it an attractive offering on the STAR Market. With success in our addressed markets, strong customer traction, and a number of new applications coming to market this year and beyond, we have significant momentum building in our business. If completed, the IPO will provide proceeds that will be invested in Tongmei to enable us to expand capacity to capture high-volume opportunities across our portfolio and develop new products to drive incremental growth and value from market expansion in 5G, data center expansion, telecommunications modernization, healthcare monitoring, microLEDs, and more," added CEO Morris Young.

12:05 EST Sony says 'Among Us' leads PS4, PS5 downloads in December in U.S., Canada, EU - Sony (SONY) said on its PlayStation blog that the top-downloaded PlayStation 5 game in the U.S., Canada, and EU in December was Innersloth's "Among Us," followed by "Spider-Man: Miles Morales" in the U.S. and Canada and EA's (EA) "FIFA 22" in the EU. Other top-downloaded PS5 games in both regions included Activision's (ATVI) "Call of Duty: Vanguard," Ubisoft's (UBSFY) "Assassin's Creed Valhalla," and Take-Two's "NBA 2K22." "Among Us" also ranked at the top of PlayStation 4 downloads in both regions for the month. Reference Link

12:00 EST GameStop falls -11.1% - GameStop is down -11.1%, or -$15.64 to $124.98.

12:00 EST Torrid falls -15.9% - Torrid is down -15.9%, or -$1.70 to $9.00.

12:00 EST BP Prudhoe Bay rises 10.0% - BP Prudhoe Bay is up 10.0%, or 48c to $5.26.

11:10 EST Sarepta trading resumes

10:51 EST Sarepta says SRP-9001 show 'statistically significant' functional improvements - Sarepta Therapeutics announced topline results from Part 2 of Study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 in 41 patients with Duchenne muscular dystrophy, 21 of whom were in the placebo crossover cohort. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. Results were presented today at the 40th Annual J.P. Morgan Healthcare Conference. SRP-9001-treated participants from the placebo crossover group scored a statistically significant 2.0 points higher on the mean North Star Ambulatory Assessment at 48 weeks compared to propensity-score weighted external controls. Mean NSAA scores from these Part 2 participants improved 1.3 points from baseline for the SRP-9001 treated group and the NSAA scores in the external control group declined 0.7 points from baseline. Additional results will be shared at a future medical congress. The safety profile of patients treated in Part 2 of Study 102 is consistent with that seen in Part 1. There were no treatment-related serious adverse events, no deaths and no study discontinuations due to an adverse event. The most common treatment-related adverse event in patients treated in Part 2 was vomiting, similar to Part 1. For patients treated in Part 1, no new safety signals emerged after two years of follow up. Study 102 remains ongoing and all participants continue to be monitored for safety in addition to longer-term assessments of functional outcomes.

10:29 EST Biogen CEO says Aduhelm Phase 3 data under review at 'top journal' - Biogen CEO Michel Vounatsos is quoted as having said at the JPMorgan healthcare conference that 220 sites are now treating patients with Aduhelm and that Aduhelm's Phase 3 data is under review at a "top journal," according to Bloomberg headlines from the event.

10:23 EST Sarepta trading halted, news pending

10:04 EST Hayward acquires Water Works Technologies Group, terms not disclosed - Hayward Holdings announced the acquisition of Water Works Technologies Groupm a manufacturer of water features including water bowls and sheer waterfalls with LED lighting options. This acquisition follows the recent acquisitions of two internet of things technology businesses, SmartPower and SmartValve. Together, these acquisitions further extend Hayward's leading position in smart, IoT-enabled technologies designed to bring greater control and ambiance to the pool while simplifying ease of use and cost of ownership. Water Works manufactures a variety of water bowls in both resin and glass in an assortment of colors and finishes as well as Sheer Waterfalls. These high-end water features all have color illumination through LED lighting options which allow Smart app coordination with other pool, spa or landscape lighting colors and shows.

10:02 EST CECO Environmental to acquire industrial flow control company GRC - CECO Environmental Corp. announced it has agreed to acquire industrial flow control company GRC. The acquisition will be integrated into the company's Effox-Flextor-Mader, Inc. joint venture with Chartwell Investments Entrepreneur & Founder Capital, LLC, the company said in a statement. The transaction is expected to close by April 2022, subject to customary closing conditions, and will be financed with a mix of cash, debt, and equity from the joint venture.

10:00 EST Owens & Minor falls -11.2% - Owens & Minor is down -11.2%, or -$5.05 to $40.03.

10:00 EST CNFinance rises 7.3% - CNFinance is up 7.3%, or 32c to $4.68.

10:00 EST Denny's announces partnership with REEF - Denny's announced that the company will partner with REEF, the largest operator of virtual restaurants, logistics, and proximity hubs in North America, to provide new delivery options from virtual kitchens in metropolitan trade areas. The company is actively coordinating with REEF on the launch of initial test market locations which will be a matter of a future announcement. Through this partnership, Denny's plans to expand its footprint across the U.S. and also be a key player in REEF's platform for breakfast offerings.

09:56 EST Aziyo Biologics Inc (Class A Stock) trading halted, volatility trading pause

09:47 EST Silvergate Capital falls -6.6% - Silvergate Capital is down -6.6%, or -$8.47 to $120.02.

09:47 EST Torrid falls -15.9% - Torrid is down -15.9%, or -$1.70 to $9.00.

09:47 EST Local Bounti rises 7.5% - Local Bounti is up 7.5%, or 38c to $5.43.

09:46 EST United Bancorp trading resumes

09:40 EST United Bancorp trading halted, volatility trading pause

09:38 EST Immix Biopharma Inc trading halted, volatility trading pause

09:35 EST Wrap Technologies receives order for BolaWrap 150 Remote Restraint devices - Wrap Technologies announced the first order for its BolaWrap 150 Remote Restraint devices through the Arizona Municipal Risk Retention Pool funding program announced on December 16, 2021. The order was placed following the announcement that the AMRRP Board of Trustees voted unanimously to approve funding to assist its member police agencies statewide in procuring BolaWrap devices for active-duty police officers. The AMRRP represents over 60 rural agencies with more than 1,800 police officers. AMRRP will fund 50% of the purchase price of the BolaWrap and the associated accessories, to help equip police officers that work for its member agencies. The agency order is for full deployment to all active-duty officers including devices, cassettes, and holsters. The Company expects to ship the order in the first quarter of 2022.

09:35 EST Discovery Communications trading halted, volatility trading pause

09:34 EST Alignment Healthcare announces preliminary inpatient utilization for Q4 - Alignment Healthcare announced that its inpatient utilization in the fourth quarter of 2021 was about 5% lower than expected, even amid COVID-19. "This further validates that our AVA health platform and differentiated care delivery model are working," said John Kao, founder and CEO, Alignment Healthcare. "Delivering high-quality care at lower costs allows Alignment to provide consistent value to its members year in and year out. We are able to do well by doing good by improving the health and well-being of our members." Additionally, its health plan membership is at 92,700 as of Jan. 1, 2022, following its annual enrollment period. The growth represents an approximately 16% increase compared to its January 2021 health plan membership. For 2022, Alignment serves 38 counties across four states, representing 7 million seniors, and offers more than 40 health plans.

09:32 EST HealthEquity announces HSA sales estimates for FY21 - HealthEquity announced estimates of HSAs, HSA assets and total accounts for its fiscal year ending on January 31, 2022, reflecting record new openings and custodial asset growth. Estimated HSAs are expected to be approximately 7.2M by January 31, 2022, up from 5.8M a year earlier; Estimated HSA assets are expected to be approximately $19.8B, up from $14.3B at the end of the prior fiscal year with approximately 35% invested compared to 29% at the end of fiscal year 2021, excluding the potential impact from market volatility for the remainder of the month of January 2022; Estimated total accounts are expected to be approximately 14.4M compared to 12.8M at the end of fiscal year 2021, not including suspended commuter accounts; Based upon current economic indicators and rate environment, HealthEquity estimates the yield on HSA cash assets to be at or above 1.55% for fiscal year 2023.; and The Company estimates that it will end its fiscal 2022 year with approximately 120,000 employer clients and 185 network partners consisting of integrated health and retirement plan partners, brokers and benefit advisors. Commenting on the results, Jon Kessler, President and CEO said, "Team Purple and our growing partner ecosystem are on track to deliver approximately 850,000 new organic HSAs this year, up a remarkable 24% from a year ago. Combined with new HSAs from Further and Fifth Third Bank, we will have welcomed nearly 1.6 million new HSA members to HealthEquity and added over $5 billion in HSA assets to our platform during fiscal 2022. More clients and partners are using our proprietary platform to connect health and wealth than ever before."

09:30 EST Seer, Discovery Life Sciences, SCIEX announce proteogenomics consortium - Seer, SCIEX, and Discovery Life Sciences announced they have signed an agreement to form the Proteogenomics Consortium, a collaboration that will enable genomics customers to more easily add deep, unbiased proteomics data to their discovery, translational and clinical studies. Through this multi-year effort, Discovery will establish, expand, and offer deep, unbiased proteomics capabilities to their existing genomics customers using the Seer Proteograph Product Suite and the SCIEX ZenoTOF 7600 platform. This will create a capacity for more than one billion peptides each year to be analyzed and cataloged, allowing the discovery of new protein variants and novel biomarkers, potentially leading to therapeutic breakthroughs. Seer and SCIEX will contribute industry-leading proprietary proteomics technologies and instrumentation, and Discovery will provide its significant scale and expertise in genomics services and biospecimens, to provide services that support population-scale plasma proteogenomic projects. Seer's Proteograph Product Suite includes proprietary engineered nanoparticles, consumables, an automation instrument, and software that enables deep, unbiased proteomics studies with an unprecedented combination of speed, scale, depth, and breadth of data. It accurately surveys thousands of proteins and millions of peptides with precision. The SCIEX ZenoTOF 7600 system is a high-resolution, accurate mass system combining the power of Zeno trap pulsing with electron activated dissolution (EAD) fragmentation technology to uncover structural information, previously inaccessible, and drive the limits of quantification achievable with accurate mass. Discovery will expand their existing biomarker discovery platform as part of their proteomics strategy, expanding the technology platforms available to their worldwide customer base. Their unique service-oriented scientific team will deliver reliable scientific insight for proteogenomic studies.

09:29 EST Five Below reports holiday period SSS up 7.7% - The company announced that net sales for the Holiday Period increased by 20.6% to $870.9M from $722.3M in the comparable nine-week period from November 1, 2020 through January 2, 2021. Comparable sales for the Holiday Period increased by 7.7%.

09:28 EST Safe-T consumer privacy solution surpasses 10,000-subscriber milestone - Safe-T Group announced that it has reached a monthly recurring revenue milestone for its recently introduced privacy solution for Apple mobile devices via the App Store, which is now serving more than 10,000 subscribers worldwide. 2021 witnessed growing demand from consumers looking for effective solutions to keep their identities private, strengthening their online safety and anonymity. Seeking to provide consumers with an alternative to existing, often slow and unreliable VPN technology, the Company's new privacy solution was launched in early 2021 through a phased product introduction program. Since its launch, the consumer privacy product has recorded significant subscriber revenue growth, averaging over 50%, quarter-over-quarter. The Company ended 2021 with more than 10,000 paid subscribers, with significant presence in the United States. Recently, the Company has seen strong interest in its solution from users in countries that are invoking more restrictive policies for online activity. To capitalize on the growing interest for enhanced consumer privacy, the Company intends to ramp-up global marketing of the product through the first half of 2022 and launching its availability on Android mobile devices and personal computers.

09:27 EST BAYOOTEC cuts frontend development time by 15% with Progress - Progress announced that BAYOOTEC, a full-service software provider based in the DACH region, is using Progress Kendo UI JavaScript component libraries to quickly build and easily customize functional, visually appealing applications for their clients. BAYOOTEC, the enterprise software division of BAYOONET AG, helps more than 800 organizations digitalize and streamline their operations by creating custom solutions that fill the missing link between their different technology tools and data sources. BAYOOTEC needed a comprehensive UI toolbox that would deliver an exceptionally intuitive and easy-to-use interface for their customers.

09:26 EST CleanSpark Joins Valkyrie Investments to discuss sustainable bitcoin mining - CleanSpark announced that CEO Zach Bradford will participate in a Valkyrie Investments webinar on sustainable bitcoin mining Thursday, January 13. The event is the first of Valkyrie's new Spotlights webinar series. Bradford will be joined by Kristy-Leigh Minehan.

09:25 EST Genprex to accelerate opening of Acclaim-1 clinical trial sites - Genprex (GNPX) announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial which combines the company's lead product candidate, Reqorsa Immunogene Therapy with AstraZeneca's (AZN) Tagrisso, as a potential innovative treatment for non-small cell lung cancer. Under a collaboration agreement with a large network of integrated, community-based oncology practices, the opening of four clinical trial sites to enroll patients in the Phase 1 portion of Genprex's Acclaim-1 clinical trial is underway, with an expectation of opening additional sites in the Phase 2 portion of the study.

09:24 EST Duck Creek Technologies expands partnership with Precisely - Duck Creek Technologies announced that Precisely has launched a new integration with Duck Creek Policy, the tenth such integration between Precisely and the Duck Creek Platform to date.

09:23 EST Clover Health reports Medicare Advantage membership growth of over 25% - Clover Health announced Medicare Advantage membership growth of over 25% versus the beginning of 2021, outpacing the overall industry growth average of approximately 10% year-over-year. Clover began January 2022 already above its previously indicated 2022 average MA membership guidance of 82,000 lives, the company said in a statement.

09:21 EST Xenon outlines key milestones for 2022 - Xenon Pharmaceuticals (XENE) outlined its key milestones for 2022. Ian Mortimer, Xenon's President and Chief Executive Officer stated, "We are entering 2022 with an immense amount of positive momentum, building upon the strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial announced in the fourth quarter of 2021. We have set clear business objectives for 2022, with a high priority placed on conducting an end-of-Phase 2 meeting with the FDA in the second quarter of 2022, finalizing our XEN1101 clinical development plans, and initiating our XEN1101 Phase 3 program in the second half of 2022 in adult patients with focal epilepsy. In addition, we are evaluating XEN1101 as a treatment for major depressive disorder, both in an investigator-led study with collaborators at Mount Sinai that is currently underway and in a company-sponsored Phase 2 clinical trial that is expected to begin in the first half of this year." Highlights and Anticipated Milestones: XEN1101: The X-TOLE open-label extension, which has been extended to three years, is expected to continue to generate important long-term data for XEN1101. Xenon is also evaluating other potential epilepsy indications for the future development of XEN1101. In addition, Xenon is collaborating with the Icahn School of Medicine at Mount Sinai to conduct an investigator-sponsored Phase 2 trial of XEN1101 for the treatment of MDD. XEN496: Xenon anticipates that the EPIK study will be completed in the first half of 2023. NBI-921352: Xenon has an ongoing collaboration with Neurocrine Biosciences (NBIX) to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor. Neurocrine Biosciences is conducting a Phase 2 clinical trial evaluating NBI-921352 in adult patients with focal onset seizures, with data expected in 2023.

09:20 EST Sienna Senior Living says 40 0f 83 residences are in outbreak - Sienna Senior Living provided an update on its operations and announced the appointment of Paul Boniferro to its Board of Directors. In recent weeks, the Omicron variant has impacted Canadians from coast to coast and further highlighted the challenges faced by the healthcare sector across the country. COVID-19/Omicron Update - As of January 7, 2022, 40 of Sienna's 83 owned or managed residences are in outbreak, with active cases of COVID-19 at 32 long-term care and 8 retirement residences. Of these residences, 23 residences have five or less active COVID-19 cases among its residents, including 10 residences with no active COVID-19 cases. An outbreak is defined as two or more confirmed cases of COVID-19 at a residence. Supported by the added protection of booster shots, the majority of residents' and team members' symptoms with respect to the new Omicron variant appear to be mild or moderate. Sienna continues to have stringent precautions in place to manage the impact of Omicron at its residences. Vaccinations - Approximately 90% of Sienna's residents and approximately 42% of Sienna's team members have received their booster dose of a COVID-19 vaccine, according to the most recent data available. In addition, the roll-out of fourth vaccine doses has commenced for eligible residents at Sienna's long-term care residences and Sienna's vaccination task force is supporting the efforts to get third and fourth doses of the vaccine to team members and residents as quickly and efficiently as possible. Staffing - The Company is actively managing staffing pressures as a result of an increased number of team members being required to self-isolate due to the high transmissibility of the Omicron variant. As a result, Sienna anticipates elevated agency staffing needs and continued cost pressures from higher agency labour costs. The Company continues to receive support from government funding in relation to incremental pandemic-related costs. Sienna's sales and marketing efforts continued their momentum in recent months, resulting in high lead generation and sustained occupancy increases with same property average occupancy reaching 85.3% in December 2021, its highest level in nearly two years. Throughout the fourth quarter of 2021, average same property occupancy levels improved each month and rent collection levels remained high.

09:18 EST Denny's sees FY21 adjusted EBITDA $84M-$86M - Sees total general and administrative expenses between $67 million and $69 million, including approximately $13.5 million related to share-based compensation.

09:17 EST Document Security retains blockchain, digital assets law firm - DSS announced its USX Holdings Company subsidiary has engaged a "leading blockchain, digital assets, and custody law practice in connection with its broker-dealer and alternative trading system as it prepares to launch an innovative marketplace for trading digital assets based on actively traded U.S. equity securities," the company said. USX Holdings, in conjunction with its legal team, will file regulatory submissions and registration statements for digital assets to be traded on the proprietary trading platform. USX Holdings is also applying for money transmitter and virtual currency activity licenses in several states to offer trading in cryptocurrencies. "We look forward to working with our legal team as we move forward on our plans to launch a digital asset exchange targeting corporate issuers, retail traders and investors, crypto hedge funds, proprietary trading firms, and other financial intermediaries. Working with the top law firm in the blockchain space will enable us to accelerate our rollout of this groundbreaking initiative," stated Jason Grady, COO of DSS. "The transformative potential of digital securities is extremely exciting, and we plan to be a major player in the space as we pursue the massive opportunity in the US for a secondary market in securities tokens."

09:17 EST Nano Dimension develops nano-particle conductive ink with XTPL - Nano Dimension announced a collaboration with XTPL to develop new nano-particle based conductive ink. Nano Dimension and XTPL will focus on the development of new nano-particle conductive ink for AME applications, enabling high conductivity and high-performance material suitable for 3D electronic printing technology for ultra-precise delivery of nanomaterials.

09:15 EST Adaptive Biotechnologies announces CFO Cohen to resign - Adaptive announced that Chad Cohen, chief financial officer, will be resigning from his role, effective on or about February 15, 2022, following the filing of Adaptive Biotechnologies' Annual Report on Form 10-K for the year ended December 31, 2021. Adaptive Biotechnologies' principal accounting officer, Kyle Piskel, will serve as interim CFO after Cohen's resignation. Adaptive Biotechnologies has initiated a search for a permanent CFO with the capabilities and qualifications to help accelerate the development and commercialization of products resulting from the insights provided by its proprietary immune medicine platform. Cohen will continue to work with Adaptive Biotechnologies and Piskel in a consulting capacity to ensure a smooth transition

09:14 EST Scopus BioPharma provides update following annual meeting of stockholders - Scopus BioPharma announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange Commission disclosing the certified voting results of the Annual Meeting of Stockholders. In addition, Scopus announced that three Scopus directors are challenging the results of the Annual Meeting as Morris Laster, M.D. and his three daughters may only own - and have been entitled to vote - 6,000 shares, less than 0.10% of their purported ownership position. Joshua Lamstein, Chairman of Scopus, stated, "The Company would like to thank its stockholders for their support at the Annual Meeting. The combination of the Lasters' own sworn statements in legal proceedings and the litigation by an affiliate of HCFP have called into question the Lasters' purported ownership position, including whether the Lasters ever owned any of the Disputed Shares, and the validity of the results of the Annual Meeting. The Company is committed to doing everything in its power to protect the interests of its actual stockholders from the nefarious and self-interested actions of the Lasters, whose only holding in Scopus may turn out to be 6,000 shares."

09:11 EST Upland Software acquires Objectif Lune for $29M - Upland Software announced that it has acquired Objectif Lune, an enterprise software company in document composition and business communication automation. The purchase price paid for Objectif Lune and related entities was $29M in cash at closing, paid out of cash on hand, and a $5.3M cash holdback payable in twelve months. Upland expects the acquisition to generate annual revenue of at least $13M, including at least $12M of recurring revenue, and will be subject to reductions for deferred revenue discount as a result of GAAP purchase accounting currently estimated at $4M for the remainder of 2022 and $1M for 2023. The price paid for the acquisition is within Upland's target range of 5-8x pro forma adjusted EBITDA and it is expected that Objectif Lune will generate at least $5.2M in adjusted EBITDA annually once fully integrated. The acquisition will be immediately accretive to Upland's adjusted EBITDA per share contributing at least $300,000 of adjusted EBITDA in the quarter ended March 31 and at least $2.6M of adjusted EBITDA for the full year 2022 ramping up quarterly as the acquisition is integrated into model across the calendar year.

09:10 EST 4D Molecular announcse FDA fast track designation granted to 4D-125 - 4D Molecular Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including X-linked Retinitis Pigmentosa. 4D-125 is a targeted and evolved R100-based product candidate, which was invented at 4DMT for efficient intravitreal delivery, and is designed to deliver a functional copy of the RPGR gene to photoreceptors in the retina.

09:09 EST Enjoy Technology appoints Vineet Gambhir as Chief People Officer - Enjoy Technology announced the appointment of Vineet Gambhir as Chief People Officer, effective January 7. Gambhir is an experienced leader in people development for high-growth businesses, with more than 20 years of human resources experience at transformative technology companies. As Chief People Officer, Mr. Gambhir will be responsible for overseeing the Company's people function and driving Enjoy's human capital strategy. He will lead Enjoy's strategic initiative to enhance its recruiting, onboarding and training processes as the Company scales its talent acquisition and development programs on a global basis to support its growth. Mr. Gambhir will join Enjoy's Enterprise Leadership Team and will report directly to CEO Ron Johnson.

09:08 EST T-Mobile acquires Octopus Interactive, terms undisclosed - T-Mobile (TMUS) announced the acquisition of Octopus Interactive, a network of interactive video screens inside Uber (UBER) and Lyft (LYFT) vehicles. Octopus Interactive helps brands reach audiences through video ads presented on screens inside rideshare vehicles. Octopus's rideshare network enables brands to execute geotargeted campaigns across a range of engaged consumers.

09:08 EST Denali Therapeutics announces program progress, expected milestones - Denali Therapeutics (DNLI) announced program progress and expected milestones for 2022. Denali's 2022 Outlook: Expected progress and key milestones in 2022 across Denali's therapeutic portfolio are summarized below. DNL310: Phase 2/3 trial for MPS II to begin patient dosing in 1H 2022. BIIB122/DNL151: Late-stage trials in Parkinson's disease. Denali and Biogen (BIIB) are collaborating to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 for Parkinson's disease. Based on the strength of the Phase 1/1b data, start-up activities are ongoing for two late-stage trials of BIIB122 in PD for which Biogen will lead operational execution. SAR443820/DNL788 and SAR443122/DNL758: Phase 2 trials in neurodegenerative and peripheral inflammatory diseases. Denali and Sanofi (SNY) are collaborating on the development of small molecules that inhibit receptor interacting serine/threonine protein kinase 1. Sanofi decided to initiate a Phase 2 trial named HIMALAYA, in participants with amyotrophic lateral sclerosis. DNL343: Phase 1b safety and biomarker data in ALS expected in mid 2022. DNL919: Advancing into first-in-human trials with safety and biomarker data expected in 2H 2022. DNL593: Advancing into first-in-human trials. Oligonucleotide TV: First nonhuman primate data further validates TV platform for brain delivery of oligonucleotides. DNL126: Announcing first preclinical biomarker data supporting development in MPS IIIA and further validating the Enzyme Transport Vehicle. Bispecific ATV:HER2: Expanding the TV platform with potential applications in oncology.

09:06 EST Wyndham Hotels & Resorts enters Poland - Wyndham Hotels & Resorts continues to expand its global footprint with its entry into Poland with the 205-room upscale Wyndham Wroclaw Old Town. Managed by Mogotel Hotel Group, a leading hotel operator in the Baltics, the property is expected to open early next month and will be located in the heart of Wroclaw's city center.

09:05 EST Midwest Holding announces strategic asset management initiative with ORIX Corp. - Midwest Holding announced the closing of a majority ownership sale of a consolidated reinsurance facility to a subsidiary of ORIX Corporation. Under the terms of the agreement, a subsidiary of ORIX USA purchased approximately 70% of Seneca Incorporated Cell, LLC 2020-01, a Midwest consolidated reinsurance cell. Midwest established SRC1 in early 2020 as the first reinsurance cell of Seneca Re, a Vermont domiciled captive reinsurance company. SRC1 has reinsured premium from its sister insurance company and Midwest subsidiary, American Life & Security Corp. ORIX Advisers, LLC, another subsidiary of ORIX USA, will be the manager of the assets underlying SRC1's reinsurance obligations going forward, replacing Midwest's asset management arm, 1505 Capital. Midwest will report the transaction in its 2021 financial statements. The transaction closed on December 30, 2021. In addition, Midwest has also established a new warehouse vehicle, SRC3, to be available for reinsurance transactions.

09:04 EST Madrigal appoints Dominic Labriola as chief data, analytics officer - Madrigal Pharmaceuticals announced that Dr. Dominic Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer. Dr. Labriola spent more than 20 years at Bristol Myers Squibb as Head of Global Biometric Sciences where he was responsible for the team overseeing the company's NASH program among many other programs.

09:02 EST 23andMe receives FDA clearance for direct-to-consumer genetic test - 23andMe Holding received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker. This is the Company's third cancer risk report clearance, following the FDA's prior authorization for 23andMe's BRCA1/BRCA2 Genetic Health Risk report and its clearance for MUTYH-Associated Polyposis, a hereditary colorectal cancer syndrome. These two reports along with the new Hereditary Prostate Cancer report have been included by the FDA in a single "Cancer Predisposition Risk Assessment System" regulation. These three 23andMe reports are the only direct-to-consumer genetic health risk reports for inherited cancers that have been authorized by the FDA for use without prescription.

09:01 EST Nemaura Medical appoints Arash Ghadar to COO - Nemaura Medical announces the appointment of Dr. Arash Ghadar as Chief Operating Officer. Prior to joining Nemaura, Dr. Ghadar spent a decade as the Technical Director of Datalink Electronics in Loughborough, England where he managed the design team as an autonomous entity within Datalink.

08:59 EST Fate Therapeutics announces FDA clearance for FT536 - Fate Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate. FT536 is derived from a clonal master induced pluripotent stem cell line engineered with four functional elements, including a novel CAR that uniquely targets the alpha3 domain of the major histocompatibility complex class I related proteins A and B. MICA and MICB are stress proteins that are expressed at high levels on many solid tumors. The Company plans to initiate clinical investigation of FT536 as a monotherapy and in combination with tumor-targeting monoclonal antibody therapy for the treatment of multiple solid tumor indications. FT536 also incorporates a novel high-affinity 158V, non-cleavable CD16 Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; an IL-15 receptor fusion that augments NK cell activity; and the deletion of the CD38 gene, which promotes persistence and function in high oxidative stress environments such as the suppressive tumor microenvironment. The multi-center Phase 1 clinical trial of FT536 is designed to determine the maximum tolerated dose of FT536 and assess its safety and clinical activity as monotherapy and in combination with one of an array of five monoclonal antibodies for the treatment of advanced solid tumors. Eligible tumor types include advanced non-small cell lung cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, and pancreatic cancer. The Phase 1 clinical protocol allows for administration of FT536 initially in up to two, 30-day cycles, with each cycle consisting of three days of conditioning chemotherapy and three weekly doses of FT536. Patients with clinical benefit may be re-treated with up to two additional cycles. Furthermore, for those patients that achieve initial clinical response, additional treatment with FT536 may be administered following disease progression. The off-the-shelf treatment regimen is designed to be administered in the outpatient setting. The expression of MICA and MICB proteins, which is induced by cellular stress, damage or transformation, has been reported for many solid tumor types. Cytotoxic lymphocytes, such as NK cells and CD8+ T cells, can recognize and bind the membrane-distal alpha1 and alpha2 domains of MICA/B, activating a potent cytotoxic response. However, cancer cells frequently evade immune cell recognition by proteolytic shedding of the alpha1 and alpha2 domains of MICA/B. A recent publication in Science (DOI:10.1126/science.aao0505) by Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that antibody targeting of the MICA/B alpha3 domains specifically prevents MICA/B shedding and restores NK cell-mediated immunity. Additionally, in a more recent publication in Cancer Immunology Research, Dr. Wucherpfennig also demonstrated that cancers with B2M and JAK1 inactivating mutations resulting in loss of MHC Class I expression can be effectively targeted with MICA/B alpha3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors resistant to cytotoxic T cells. The Company's FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics.

08:55 EST MiMedx outlines key strategic milestones for 2022 - Achieve annual growth target across the Company's vibrant commercial business: Expand the Company's international footprint with the initial launch of EPIFIX in Japan; Commence Phase 3 KOA program, with two clinical trials; Implement rigorous Current Good Manufacturing Practice standards throughout entire supply chain as a key market differentiator; Continue to advance the scientific body of evidence substantiating clinical efficacy, economic viability and underlying mechanism of action for our PURION processed placental tissue platform through additional peer-reviewed publications, including rigorous scientific research and clinical studies; Launch two new, organic products in the U.S.: AMNIOEFFECT and Placental Collagen Matrix, facilitating expansion into additional areas of significant unmet clinical need.

08:54 EST CoreCivic awarded contract with the State of Arizon at La Palma - CoreCivic announced that it has been awarded a new contract with the State of Arizona for up to 2,706 adult male inmates on behalf of the Arizona Department of Corrections, Rehabilitation & Reentry at the Company's 3,060-bed La Palma Correctional Center in Eloy, Arizona. The new management contract has an initial term of five years, with one extension option for up to five years thereafter upon mutual agreement. The Company and ADCRR are currently working on a ramp plan that is expected to begin late in the first or early in the second quarter of 2022. Upon full utilization of the new contract the Company expects to generate approximately $75 million to $85 million in annualized revenue.

08:53 EST Converge Technology acquires Paragon Development Systems - Converge Technology Solutions is pleased to announce it has acquired PDS Holding Company, a Delaware corporation, and its wholly-owned subsidiaries, including Paragon Development Systems, a Wisconsin-based organization focused on fueling digital transformation. Converge acquired PDS from Mason Wells, a private equity firm based in Milwaukee, Wisconsin. With incredible expertise supporting Enterprise Solutions, Managed Services, and true Digital Workplace platforms, Paragon Development Systems works synergistically to leverage the strength of its solution architects and engineering teams to design the right solutions to drive successful strategic outcomes. PDS offers solutions ranging from cloud and security to servers and infrastructure to virtualized work environments and remote work. PDS serves clients in three distinct markets (healthcare, public sector, and corporate), advising and assisting with unique information technology needs in upgrading and modernizing core business technology infrastructure on the continuing journey of innovation and digital transformation.

08:49 EST Amedisys announces Kusserow will retire as CEO, appoints Gerard as successor - Amedisys announced that Chairman and Chief Executive Officer, CEO, Paul Kusserow will retire as CEO on April 15th, 2022. Upon his retirement as CEO, Kusserow will continue to serve as Chairman of the Board of Directors, and current President and Chief Operating Officer , Chris Gerard, will assume the role of President and CEO and join the Board of Directors following the succession planning process that began in early 2021.

08:48 EST Advent Technologies enters distribution, service agreement with Calscan - Advent Technologies announced it has signed a distribution and service agreement with Calscan Solutions, an Alberta, Canada industrial service company focused in the oil field industry with a number of products, including methane emissions mitigation instrumentation & controls, as well as services.

08:46 EST Iovance appoints Raj Puri as EVP, regulatory strategy, translational medicine - Iovance Biotherapeutics announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri will begin his employment with the Company toward the end of the first quarter of 2022. For more than 19 years, Dr. Puri has served as the director of the Division of Cellular and Gene Therapies in the Office of Tissues and Advanced Therapies at the United States Food and Drug Administration in its Center for Biologics Evaluation and Research. He is also a Chief of Tumor Vaccines and Biotechnology Branch within DCGT.

08:41 EST Oric Pharmaceuticals expects cash to fund operations into first half of 2024 - As of December 31, 2021, cash, cash equivalents and investments totaled $280.8M.

08:40 EST VirTra receives orders from two foreign countries totaling $2.7M - VirTra has received two foreign country orders totaling $2.7M: one for $1.6M and another for $1.1M. Both orders are for simulators, software, content and associated training tools. Both purchase orders include the delivery of multiple simulators, Threat-Fire real-world consequence devices, drop-in weapon recoil kits, and other integrated tools designed for enhanced realism needed for effective training. The orders include installation and training courses to facilitate the operation of each simulator and its accessories. The first order is planned to be delivered in early 2022 and the second order is expected to be delivered in spring 2022. Neither of these orders are related to the recent standing offer awarded to VirTra by the government of Canada.

08:39 EST Oric Pharmaceuticals provides update, key upcoming milestones - ORIC Pharmaceuticals provided program updates and announced upcoming key milestones that are expected to substantially broaden and advance the company's clinical pipeline. Program Updates and Milestones: ORIC-101: Glucocorticoid Receptor Antagonist: The company expects to provide an update on two Phase 1b trials in the first half of 2022. ORIC-533: CD73 Inhibitor: Based on strong mechanistic rationale and compelling preclinical single agent activity in bone marrow cells from patients with multiple myeloma, the company has initiated a Phase 1b trial as a single agent in multiple myeloma and expects to report initial data in the first half of 2023. ORIC-114: EGFR/HER2 Inhibitor - The company expects to report initial Phase 1b data in the first half of 2023. ORIC-944: PRC2 Inhibitor - The company plans to pursue a single agent clinical development plan in metastatic prostate cancer and expects to report initial Phase 1b data in the first half of 2023. Anticipated Program Milestones: ORIC anticipates the following upcoming milestones: ORIC-101: Updates from two Phase 1b combination trials in 1H 2022; ORIC-533: Initial Phase 1b data in 1H 2023; ORIC-114: Initial Phase 1b data in 1H 2023; ORIC-944: Initial Phase 1b data in 1H 2023; and New program and/or indication to be announced in 2022.

08:38 EST FPT, Microvast under hood of new IVECO BUS electric crossway - FPT Industrial, with its partner Microvast Holdings will provide the complete battery system for the new Crossway Low Entry city and intercity bus produced by IVECO BUS, also a brand of Iveco Group and a leading manufacturer of buses and coaches. The contract award was achieved based on the 2019 agreement that encompasses an industrial and commercial cooperation between Microvast and FPT Industrial, with the latter leading the development of mechanical and thermal integration and industrialisation of high-voltage battery packs for commercial vehicles. For the IVECO BUS Crossway Low Entry Electric, Microvast designed and FPT Industrial industrialised, validated, and certified a high energy density battery pack that ranges from 400 to 466 kWh, depending on operative mission requirements. This new generation battery pack will set an industry standard in terms of energy density and charging capacity and will provide the Crossway LE Electric with up to ten years of battery life. This marks an important step forward in a shared "electrification journey". The IVECO BUS Crossway LE Electric project complements that of the new IVECO e-Daily, which will be launched at the end of 2022. The new electric Daily will be equipped with a modular battery concept with 1 to 3 batteries ranging from 37 to 111 kWh, pioneering the cooperation between Microvast and FPT Industrial in this first application that aims to set the zero-emission standard in the cab-chassis segment.

08:37 EST Gilead in trial pact with Merck to evaluate Trodelvy -Keytruda combo in NSCLC - Gilead Sciences (GILD) announced it has entered into two clinical trial collaboration and supply agreements with Merck (MRK) to evaluate the combination of Gilead's Trop-2 targeting antibody-drug conjugate, ADC, Trodelvy, sacituzumab govitecan-hziy, and Merck's anti-PD-1 therapy KEYTRUDA, pembrolizumab, in first-line metastatic non-small cell lung cancer NSCLC. As part of the collaboration, Merck will sponsor a global Phase 3 clinical trial of Trodelvy in combination with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC. Additionally, the companies recently established an agreement whereby Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line NSCLC. "We're excited to broaden our clinical collaborations with Merck to investigate Trodelvy in combination with KEYTRUDA in another cancer where there is tremendous need for novel combinations to help improve patient outcomes," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "This partnership builds on our ambition of providing alternatives to traditional chemotherapy with Trodelvy containing regimens across some of the most difficult-to-treat cancers." These agreements follow a collaboration, established in October 2021, to investigate Trodelvy in combination with KEYTRUDA as first-line treatment for people with locally advanced or metastatic triple-negative breast cancer, TNBC. The use of Trodelvy for the treatment of NSCLC and the use of Trodelvy in combination with KEYTRUDA for any use is investigational, and the safety and efficacy for these uses have not been established or approved by regulatory agency globally.

08:36 EST BioNTech, Crescendo Biologics announce global collaboration - BioNTech and Crescendo Biologics announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The initial term of the discovery collaboration is three years. Crescendo will contribute its platform to deliver fully human heavy-chain antibody domains against targets nominated by BioNTech. "Crescendo's platform provides excellent properties for exploiting novel targets and target combinations which we believe has great potential for the development of multi-specific mRNA and engineered cell-based therapies in a variety of disease areas," said Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. "We are excited to begin working with Crescendo to further strengthen and expand our multimodal immunotherapy portfolio and deliver breakthrough precision medicines for patients." Under the terms of the agreement, Crescendo will receive $40M upfront, including a cash payment and an equity investment from BioNTech, as well as research funding for the period of the collaboration. BioNTech will be responsible for global development and hold exclusive worldwide commercialization rights on any products arising from the collaboration. Crescendo will be eligible to receive development, regulatory and commercial milestones up to a total of more than $750M, in addition to tiered royalties on global net sales.

08:35 EST Blacboxstocks announces $2.5M stock repurchase plan - Blackboxstocks announced that the company's board of directors has approved a stock repurchase program for up to $2.5M of the company's common stock. The repurchase plan will expire on December 31. The timing and actual number of shares repurchased will depend on a variety of factors including but not limited to share price, trading volume, general business and market conditions as well as other potential investment opportunities. The repurchase program will be executed consistent with the company's capital allocation strategy, which will continue to prioritize aggressive investments to grow the business.

08:33 EST Cara says Difelikefalin Phase 3 trial meets primary, secondary endpoints - Cara Therapeutics announced that its licensing partner Maruishi Pharmaceutical Co., Ltd., and its sublicensee Kissei Pharmaceutical Co., Ltd., confirmed the primary endpoint was achieved in a Japanese Phase 3 clinical study of difelikefalin injection for the treatment of pruritus in hemodialysis patients. In the Phase 3 study, 178 patients were administered difelikefalin or placebo for 6 weeks followed by an open-label extension period of difelikefalin administration for 52 weeks. The primary endpoint, change in itch Numerical Rating Scale score, and the secondary endpoint, change in itching scores of Shiratori severity criteria, were significantly improved from baseline compared to the placebo group. Difelikefalin was well-tolerated. KORSUVA injection was approved by the U.S. Food and Drug Administration in August 2021 for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Cara's U.S. commercial partner Vifor Pharma is on track to launch KORSUVA injection in the U.S. early in the second quarter of 2022. In addition, the Marketing Authorization Application for difelikefalin injection for the treatment of pruritus associated with chronic kidney disease in hemodialysis patients is undergoing review with the European Medicines Agency.

08:33 EST SpartanNash appoints Amy McClellan as chief marketing officer - SpartanNash announced Amy McClellan has been promoted to senior VP and chief marketing officer, effective immediately. McClellan will lead the marketing function and report to SpartanNash president and CEO Tony Sarsam. McClellan joined SpartanNash in 2019 when the company acquired Martin's Super Markets.

08:32 EST CBIZ acquires Marks Paneth, terms not disclosed - CBIZ announced that it has acquired the non-attest assets of Marks Paneth LLP, effective January 1, 2022. Concurrent with this transaction, Mayer Hoffman McCann P.C., a national independent CPA firm that works closely with CBIZ, announced the acquisition of the attest assets of Marks Paneth LLP. The transaction is expected to add approximately $138M of revenue to CBIZ in 2022. Eliminating the impact of the transaction related costs and first year integration costs, the contribution to earnings per share in 2022 is expected to be approximately 10c, growing to a range of 20c-25c by 2025, after all remaining transition related integration costs are addressed. On a GAAP reported basis the transaction is expected to have minimal impact on earnings per share in 2022, but is expected to be significantly accretive after first year transaction and integration costs are incurred. Eliminating the impact of transaction costs and first year integration costs, EBITDA in 2022 is expected to be within a range of 11%-12% of revenue, growing to a range of 16%-18% of revenue by 2025.

08:30 EST Cerence powers AI Assistant in Nio's ES8 - Cerence announced that NIO will deploy Cerence conversational AI in its ES8 full-size SUV as the carmaker expands to Norway.

08:29 EST Kiniksa expects cash to fund operations into 2024 - Kiniksa's year-end 2021 cash, cash equivalents and short-term investments of approximately $182M.

08:28 EST Protara Therapeutics appoints Jathin Bandaria as CMO - Protara Therapeutics announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer.

08:26 EST Avicanna appoints Stephen Kim as CLO, general counsel - Avicanna USA is pleased to announce the appointment of Stephen Kim as the Avicanna's Chief Legal Officer & General Counsel. Prior to joining Avicanna, Mr. Kim held various roles of progressive responsibility at global biotechnology and pharmaceutical companies including Bayer Inc., Celgene Corporation, and Indivior Inc., and also held roles as an associate with leading US and International law firms in New York City and Toronto.

08:23 EST Singular Genomics partners with New England Biolabs - Singular Genomics Systems announced a partnership with New England Biolabs to validate its NEBNext kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform. High-quality, high-yield library preparation is a critical first step towards optimizing NGS workflows. NEB is a recognized leader in the discovery and production of enzymes for molecular biology applications with renowned products in sample preparation for NGS. NEBNext kits are designed and quality controlled to improve yields and library diversity, using a broad range of input amounts from a wide variety of sample types.

08:22 EST Westhaven Gold completes initial MRE at Shovelnose Gold Property - Westhaven Gold announced the results from its Mineral Resource Estimate at its 100% owned 17,623-hectare Shovelnose Gold Property. The Shovelnose Gold Property is located within the prospective Spences Bridge Gold Belt, which borders the Coquihalla Highway 30 km south of the City of Merritt, British Columbia. The initial open-pit constrained MRE reported below is of the South Zone, and was completed by P&E Mining Consultants Inc., based on a total of 145 surface drill holes, 25,920 drill core analyses, 3,302 bulk density measurements, and preliminary metallurgical testwork. Shovelnose South Zone MRE Highlights: 791,000 ounces of gold and 3,894,000 ounces of silver Indicated. 263,000 ounces of gold and 1,023,000 ounces of silver Inferred. 75% of the MRE in the higher confidence Indicated classification: 10.60 million tonnes at 2.47 g/t for 841,000 gold equivalent ounces. Average AuEq grade of Indicated MRE is 7 times higher than the cut-off grade, demonstrating excellent potential for future economic extraction. Indicated mineralization is largely associated with the individual vein zones, whereas the Inferred is associated with the broader Veinlet Domain. This MRE is based on potential open-pit extraction - an MRE based on potential underground mining is in preparation and will be reported in the coming months. South Zone is just one of the many known mineralized zones on the Shovelnose Gold Property. Shovelnose is situated off a major highway, near grid power, rail, large producing mines, and within easy commuting distance from the City of Merritt.

08:21 EST SuperCom announces new government electronic monitoring contract in Wyoming - SuperCom announced that it has secured a new electronic monitoring contract in Wyoming. The contracting agency is an Adult and Juvenile Probation Agency and plans to use SuperCom's PureTrack GPS smartphone products to monitor their case load for location compliance. The contract is structured as a recurring per unit per day lease model, with billing at the end of each month.

08:20 EST Adamis Pharmaceuticals submits fast track application to FDA for tempol - Adamis Pharmaceuticals announced the submission of a Fast Track Application to the U.S. Food and Drug Administration for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied in a Phase 2/3 clinical trial in adult patients with confirmed COVID-19 infection. Tempol has been shown to have antiviral, anti-inflammatory, and antioxidant activity. Although recent oral antiviral drugs have been approved by the FDA, the Company believes that Tempol would provide an unmet medical need because of its unique mechanism of action and safety profile. Dr. Dennis Carlo, President and Chief Executive Officer of Adamis, commented, "Our ongoing clinical trial is continuing, as we see a surge in COVID-19 infections in the U.S. and worldwide. Concerns have been expressed about potential safety questions for EUA approved antivirals such as mutagenesis and drug-drug interactions. We are thus applying for Fast Track designation to the FDA to expedite the regulatory approval pathway for Tempol. Because Tempol has both anti-inflammatory and antiviral effects, we believe that Tempol fulfills an unmet medical need as an oral agent, focusing on multiple aspects of the pathogenesis of COVID-19 disease."

08:18 EST Destination XL reports $106.6M sales for 9-week holiday sales period - Destination XL Group announced the following results for the 9-week holiday sales period ended January 1, 2022. Total sales were $106.6 million compared to $78.4 million for the 9-week holiday sales period ended January 2, 2021 and $103.1 million for the 9-week holiday sales period ended January 4, 2020. As compared to fiscal 2019, comparable sales in our omni-channel retail business for the same 9-week holiday period increased 11.4%, primarily due to an increase in comparable sales from our direct business of 32.0% and an increase in comparable store sales of 3.2%. This comparable sales increase of 11.4% was partially offset by closed stores and a decrease in wholesale revenues, resulting in the 3.4% increase in total sales for the 9-week holiday period as compared to the same period of fiscal 2019.

08:16 EST Cognition Therapeutics provides update on goals for 2022 - Cognition Therapeutics provided an outlined upcoming milestones anticipated in the year ahead. Key 2022 Goals and Initiatives: Progress the Phase 2 Alzheimer's Clinical Trials Consortium study with 540 early-stage AD patients, assessing cognition and biomarkers; Enroll the final cohort in the ongoing SHINE trial recruiting 120 patients with mild-to-moderate Alzheimer's disease; Expand the pipeline with Phase 2 dry AMD study and DLB studies; and Advance preclinical work in Parkinson's disease evaluating two -2 modulators for clinical development;.

08:15 EST InflaRx announces new pipeline program INF904 - InflaRx announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. InflaRx recently has been granted a composition of matter patent for INF904 and associated compounds by the US Patent and Trademark Office and has completed IND-enabling studies that demonstrated no obvious toxicological findings even in the highest dose groups in required GLP toxicity analyses. In these preclinical studies, oral INF904 showed higher plasma exposure in animals, including non-human primates, and improved inhibitory activity in a hamster neutropenia model compared to the marketed C5aR inhibitor. Anti-inflammatory therapeutic effects in several preclinical disease models were also demonstrated by INF904. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments showed INF904 has substantially less inhibition of the cytochrome P450 3A4/5 enzymes, which play an important role in the metabolism of a variety of drugs, including glucocorticoids. InflaRx expects to initiate a Phase I program in the second half of 2022 and plans to study INF904 in complement-mediated, chronic autoimmune and inflammatory diseases where oral administration is the preferred choice for patients.

08:14 EST Whole Earth Brands appoints Duane Portwood as CFO - Whole Earth Brands announced the appointment of Duane Portwood as Chief Financial Officer, effective January 10, 2022. Mr. Portwood will report to Whole Earth Brand's Chief Executive Officer, Albert Manzone. Most recently, he was CFO for Tegra Global, a private sports apparel manufacturer.

08:14 EST Singular Genomics partners with Dovetail Genomics - Singular Genomics Systems announced a partnership with Dovetail Genomics to validate its proximity ligation kit portfolio, representing the leading methods to unlock access to 3-D genome architecture, with the G4 sequencing platform. The 3-D genome architecture at the nucleosome level is critical for understanding the regulation of gene expression. Dovetail's best-in-class products capture this 3-D genome architecture alongside primary sequence information using NGS. The long-range genomic information captured by Dovetail technology will enable more comprehensive detection of structural variation and chromosome-scale phasing on the Singular Genomics platform.

08:13 EST Landsea Homes closes on 200 new homesites in Palm Bay, Florida - Landsea Homes announced that it has closed on the land purchase for 200 additional homesites in Country Club Estates. This acquisition will become the fifth and final phase of the luxurious gated community in Palm Bay, Florida. This new phase at Country Club Estates is planned to include 154 detached single-family homes and 46 attached duplex single-family homes. Landsea Homes quickly sold out phases one through three at Country Club Estates, and is currently developing phase four, which consists of 68 homes. Site development for phase five is planned to commence in Q4 2022, followed by start of sales and home construction in early 2023.

08:13 EST Sesen Bio appoints Minori Rosales as chief development officer - Sesen Bio (SESN) announced the appointment of Minori Rosales as chief development officer as of January 24. Rosales will be responsible for medical and clinical strategic and operational leadership across the organization, including leading and executing an additional Phase 3 clinical trial for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. She brings over 15 years of clinical experience in pharmaceutical development, most recently as VP, clinical research at MacroGenics (MGNX), where she oversaw clinical development, including execution of clinical studies and management of global clinical safety and compliance, and led interactions with regulatory agencies.

08:11 EST Royalty Pharma provides business update - Royalty Pharma provided an update on its business performance. "I am very pleased with the performance of Royalty Pharma in 2021," said Pablo Legorreta. "We strengthened our longstanding leadership position, delivered impressive financial results and deployed substantial capital on new royalty transactions which will help drive future growth. Given the extraordinary pace of medical advances and our unique role at the heart of funding life science innovation, I am confident that we will deliver attractive, compounding growth in the coming years." Royalty Pharma has previously disclosed that it expects to deploy approximately $7B in capital on new royalty transactions over the period 2020 to 2025. Given the rapid pace of life science innovation - and the accompanying demands for capital from the biopharma industry - the company is tracking well ahead of its plan. In total, through these transactions, 20 therapies have been added to Royalty Pharma's portfolio. These new medicines are expected to make a significant contribution to the company's financial performance in the coming years.

08:10 EST EbixCash appoints Uma Shankar to board of directors - EbixCash Private Limited announced the appointment of Ms. Uma Shankar, as a new independent director to the EbixCash Board. Uma is a career banker, having retired as Executive Director at Reserve Bank of India after serving RBI for 37 years. Uma is presently an Independent Director on the Boards of Karnataka Bank as well as IDBI Capital Markets and Securities Ltd.

08:10 EST Gilat Satellite announces extension to revenue managed services project - Gilat Satellite Networks announced that the Company received a 12-month extension on its recurring revenue managed services 4G cellular backhaul project with a leading Mobile Network Operator in Mexico.

08:08 EST Medtronic says Evolut PRO TAVR system approved in China - Medtronic announced the National Medical Products Administration has approved the CoreValve Evolut PRO TAVR system for the treatment of severe aortic stenosis for symptomatic patients in China who are at high or extreme risk for open heart surgery. As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival, low rates of stroke, minimal paravalvular leak and excellent hemodynamics. Full commercial launch is anticipated in early calendar year 2022.

08:08 EST Emerita Resources reports publication of resolution by Huelva Province - Emerita Resources announces that the Andalucian Environment Department in Huelva Province has issued its resolution and published it in the official gazette approving the Company's diamond drill plan for the west side of the Iberia Belt West project on January 7, 2022 such that the entire Project is now permitted for drilling. This portion of the IBW Project hosts the large Romanera deposit and the El Cura deposit and as such this is an important step for the ongoing evaluation of the IBW Project. The publication in the gazette marks the commencement of a 30 business day period during which the reclamation plan for the drill sites are published on the government web site and available for comment. The application process in Spain requires a comprehensive exploration plan as well as a reclamation plan for the drill pads and the reclamation plan is published on the government web site for public viewing for a period of 30 days prior to issuing the permits. Permitting the west side of the project required a more involved process than the Infanta area where the Company has been drilling. The Company completed all studies required by the process including archaeological, flora and fauna studies and has written support from the two municipalities, Pueblo de Guzman and Paymogo, that encompass the project included in the filing documents. Once issued, the permits are valid for the duration of the license. The Company already has agreements arranged with local landowners for access to the drill sites in order that work can commence immediately upon receiving the permits. Emerita presently has a contract for five drills on the IBW Project and will add three more drills bringing the total to eight, to coincide with the issuing of this permit in order to complete the drilling required for a NI 43-101 compliant mineral resource estimate as quickly as practical.

08:06 EST iTeos Therapeutics appoints Yvonne McGrath as CSO - In the role of chief scientific officer, Dr. McGrath will be responsible for the continued advancement of iTeos's pipeline of immunotherapy candidates in advanced cancers. She has served as vice president of R&D since June 2020, bringing more than 20 years of experience in immuno-oncology, clinical development and R&D.

08:04 EST Black Diamond Therapeutics announces strategic priorities, expected milestones - Black Diamond Therapeutics announced a strategic pipeline update and outlined its expected upcoming milestones. Pipeline Updates and Expected Milestones: BDTX-1535: Black Diamond announced ahead of schedule the submission of its Investigational New Drug application to the US Food and Drug Administration for BDTX-1535 and expects to initiate the Phase 1 study of BDTX-1535 in the first quarter of 2022, subject to allowance of the IND by the FDA; The Company expects to provide a clinical data update on BDTX-1535 in the second half of 2023. BDTX-189: BDTX-189 is designed as a MasterKey inhibitor targeting families of oncogenic mutations in EGFR and HER2; Clinical data obtained from the MasterKey-01 study to date have demonstrated a favorable safety profile for BDTX-189; Due to the rapid evolution of the treatment landscape, the Company has decided to gate the initiation of the Phase 2 portion of the MasterKey-01 study and determine next steps in development based on further clinical data obtained from the safety expansion cohort at the recommended Phase 2 dose; The Company expects to provide further guidance on the BDTX-189 program in 2022. BRAF Program: Black Diamond is developing a CNS-penetrant BRAF inhibitor against a family of Class I, II, III canonical and non-canonical mutations. The Company's lead BRAF compound is designed to be highly selective, potent and to avoid paradoxical activation; Black Diamond anticipates the initiation of IND-enabling studies for the BRAF program in 2022. MAP Discovery Engine: The Company continues to focus on building its Mutation-Allostery-Pharmacology Discovery Engine to exploit mutant onco-protein conformations for the delivery of selective MasterKey therapies, with a focus on developing a MasterKey inhibitor that spares wild type fibroblast growth factor receptor 1 while inhibiting FGFR2 and FGFR3 mutant families, as well as other preclinical stage programs.

08:03 EST Bitfarms buys 1,000 bitcoin - Bitfarms provides a Bitcoin purchase and treasury update. Emiliano Grodzki, Bitfarms Founder and Chief Executive Officer, said, "Our guiding company strategy at Bitfarms is to accumulate the most Bitcoin for the lowest cost and in the fastest amount of time for the benefit of our shareholders. To that end, we continually optimize our capital allocation. With the dip in BTC while mining hardware prices remain high, we seized the opportunity to move cash into BTC. We continue to be committed to executing our operational growth strategy and delivering our goal of 8 exahash/second by the end of 2022."bDuring the first week of January 2022, Bitfarms purchased 1,000 BTC for US$43.2 million. This increased the BTC holdings 30% to over 4,300 as of January 10, 2022. For reference, 1,000 BTC is roughly equivalent to the amount Bitfarms added to the treasury in the third quarter of 2021 and again in the fourth quarter of 2021.

08:03 EST TScan Therapeutics outlines 2022 priorities - TScan Therapeutics announced that the Company plans to begin its first clinical trials this year. As forecasted, in December 2021 TScan filed INDs for TSC-100 and TSC-101, its TCR-T programs to prevent relapse in leukemia patients following hematopoietic cell transplants. In addition, TScan is outlining here its priorities for 2022 across its pipeline of solid and liquid tumors as well as infectious disease. 2021 Accomplishments and 2022 Pipeline Objectives: Liquid Tumor Programs: TScan's two lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are designed to target HA-1 and HA-2, respectively, and treat patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplantation. During the fourth quarter of 2021, the Company completed investigational new drug-enabling studies and submitted IND applications to the U.S. Food and Drug Administration for TSC-100 and TSC-101. Following the IND submissions and pending acceptance by the FDA, the Company expects to initiate Phase 1 clinical trials for TSC-100 and TSC-101 in the first half of 2022, with preliminary data expected in the second half of 2022. In December 2021, the Company shared clinical trial designs for TSC-100 and TSC-101 in a poster at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The Company provided further detail on the clinical rationale and trial design for the program in a virtual event with TScan management and Yi-Bin Chen, M.D., M.S., Director, Hematopoietic Cell Transplant and Cell Therapy Program, Allan B. Rogers, Jr. and Cara J. Rogers Endowed Chair, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School. Solid Tumor Programs: TScan's TSC-2xx series of TCR-T therapy candidates include a combination of known targets, such as HPV16 for TSC-200, PRAME for TSC-203, and MAGE-A1 for TSC-204, as well as targets that are novel antigens for TCR-T therapy, such as those for TSC-201 and TSC-202. TScan plans to present initial preclinical data on the TSC-2xx series at a medical meeting in the first half of 2022. TScan plans to progress IND-enabling studies for the TSC-2xx series and submit multiple IND applications during the second half of 2022. Among these will be TSC-200 for HPV, which is a validated cancer target found in every cell of HPV-positive tumors, including many cases of head & neck and cervical cancer. Using its TargetScan platform, TScan discovered a novel HLA-C*07:02-restricted epitope encoded by the well-known cancer/testis gene MAGE-A1. This cancer-specific gene is frequently overexpressed in a wide variety of solid tumors, including as many as 45% of head & neck cancers, 50% of melanomas, 50% of cervical cancers and 50% of non-small cell lung cancers. In late 2021 TScan announced a new program, TSC-204, for MAGE-A1 that will include multiple TCRs for different HLA-restricted epitopes on this target. TScan believes that it is the only company with a disclosed TCR program in MAGE-A1 for HLA types other than A*02:01. The Company anticipates filing an IND for TSC-204 in the second half of 2022. In 2023, the Company plans to release initial clinical data for the TSC-2xx series TCRs, as well as file further INDs for additional programs in this series. Infectious Disease Program:Research is continuing into potential T cell focused COVID-19 vaccine constructs utilizing TScan's novel T cell target discoveries. The Company is currently conducting IND-enabling activities for this program and will provide an update in 2022. Proprietary Platform: In 2021, using its proprietary TargetScan discovery platform, TScan identified over 110 novel solid tumor targets in tumor samples from patients who have responded to immunotherapy. The Company has already developed an extensive library of known and novel solid tumor targets across different HLA types named ImmunoBank. In 2022, the Company will provide a further update on the progress of its ImmunoBank, which will include an even greater array of validated novel cancer targets across multiple HLA types. This will allow the Company to develop a pipeline of product candidates for highly prevalent solid tumor indications that allow for multiplexing across targets and HLAs to provide durable responses to a majority of patients. TScan completed the construction and validation of a 7,000 square-foot state-of-the-art GMP manufacturing facility to manufacture all necessary Phase I/II supply for its TCR-T therapies. This facility supported the Company's first two IND filings and provides sufficient production capacity to supply product for all planned Phase I and II clinical studies for the liquid and solid tumor programs

08:01 EST Autolus Therapeutics announces 2022 priorities - Autolus Therapeutics announced its 2022 corporate priorities and provided guidance. "We are on track to complete patient recruitment in the FELIX study of obe-cel in adult ALL patients with the first data expected around the middle of the year," said Dr. Christian Itin, chief executive officer of Autolus. "This study is the key driver for the Company over the coming months and we are working diligently to shape the product profile and the commercial strategy of obe-cel, whilst laying the foundation for progressing our other differentiated CAR T cell products. We are very excited about the year ahead, which could be a transformational year for Autolus." Key Anticipated Clinical Milestones: Updates on the FELIX trial, where Autolus is evaluating obe-cel in r/r adult ALL patients. The trial is currently enrolling patients into the Phase 2 portion. Autolus expects data from the Phase 2 trial to be available in 2022; Updates from the ALLCAR19 extension trial in patients with r/r B-NHL and CLL and longer-term follow-up of the fully enrolled r/r adult ALL cohort expected in H1 2022; Updates on the obe-cel Phase 1 trial, CAROUSEL, in Primary CNS Lymphoma in Q1 2022; Clinical data from the AUTO1/22 CARPALL extension trial in pediatric ALL expected in H1 2022 with longer follow up in H2 2022; Updates on the AUTO4 Phase 1 trial in TRBC1+ Peripheral TCL expected in H1 2022; Phase 1 trials are expected to be initiated in H1 2022 with AUTO6NG in Neuroblastoma and AUTO8 in Multiple Myeloma

08:00 EST Frontier Medicines advances first program under AbbVie partnership - Frontier Medicines Corporation announced the first target for the development of a small molecule inhibitor is advancing into the lead generation phase under the company's global partnership with AbbVie. The global partnership was established in December 2020 to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against certain high-interest, difficult-to-drug protein targets.

07:58 EST European Wax Center provides update ahead of presentation at ICR conference - European Wax Center provided an update ahead of its virtual presentation at the 24th Annual ICR Conference. David Berg, Chief Executive Officer of European Wax Center, Inc., stated: "I am extremely proud of our development team for delivering 57 net new centers in fiscal 2021, nearly all of which were opened by existing franchisees. We believe this reflects our strong relationship with the network and their steadfast commitment to our future growth. We executed significant multi-unit commitments and ended the year with our deepest pipeline ever of more than 330 locations. Within our centers, we continued to delight our guests with excellent service in a trusting environment, leading to considerable growth in new guests versus 2019. We continue to monitor the impact of COVID and its variants, and we expect fiscal 2022 financial performance at least in line with our long-term growth targets. Most importantly, we remain focused on the significant opportunity ahead to leverage our leadership position in out-of-home waxing and our asset-light business model to fuel value creation for all European Wax Center stakeholders."

07:57 EST Tiziana Life Sciences enrolls second patient in ongoing treatment of SPMS - Tiziana Life Sciences announces that the U.S. Food and Drug Administration allowed enrollment of a second patient in the ongoing clinical treatment of secondary progressive multiple sclerosis, SPMS, with intranasally administered foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women's Hospital, Harvard University, Boston, MA. The first patient treated under this program completed 3 out of 6 months of dosing. Interim data suggest that the treatment was well-tolerated with a favorable clinical response. As part of the regulatory process, three-month safety data were submitted to the FDA, seeking permission to treat an additional patient under an Individual Patient Expanded Access Investigational New Drug Application, which has been allowed. Treatment of the second patient is expected to begin during January 2022 with interim clinical data after 3 out of 6 months of treatment expected in April 2022. The treatment plan will remain unchanged as per the original IND. The ongoing treatment of the first patient continues, and six months of dosing is expected to be completed by the end of March 2022. To date, this patient has not shown signs of treatment intolerance or toxicities and appears to be responding well to treatment. The brain imaging data, as analyzed by PET, show reduction in microglial cell activation.

07:54 EST Passage Bio announces 2022 research, clinical development goals - Passage Bio will share the company's 2022 outlook in a presentation today at the 40th Annual J.P. Morgan Healthcare Conference. Specifically, the company will provide an update on the status of its clinical programs, its CNS research pipeline, and additional key initiatives, including investment in a pilot manufacturing suite. Key Anticipated Company Highlights in 2022 Clinical Programs: Imagine-1 - Global Phase 1/2 Trial for PBGM01 for GM1 Gangliosidosis: Plan to deliver at 18th Annual WORLDSymposium a late-breaker presentation of additional safety and biomarker data as well as preliminary clinical results for Cohort 1 on February 11; and a presentation on the clinical trial design on February 9. Expect to dose first patients in Cohort 2 in early 2022. upliFT-D - Global Phase 1/2 Trial for PBFT02 for Frontotemporal Dementia with Granulin Mutations: Expect to dose first patient in early 2022. GALax-C - Global Phase 1/2 Trial for PBKR03 for Krabbe Disease: Expect to dose first patient in early 2022; Plan to present the clinical trial design at the 18th Annual WORLDSymposium on February 9. Research-Stage Pipeline: Plan to submit an Investigational New Drug application for the Phase 1/2 clinical program for metachromatic leukodystrophy in mid-year; Advance pipeline programs for amyotrophic lateral sclerosis, Charcot-Marie-Tooth Type 2A, Parkinson's disease, Canavan disease and Huntington's disease; Progress target identification research programs for Alzheimer's and temporal lobe epilepsy; Evaluate new product candidate programs with the University of Pennsylvania's Gene Therapy Program to continue to expand pipeline in 2022; Passage Bio has a total of 17 program license options with GTP, and has thus far exercised nine of these options Manufacturing: Operationalize new pilot manufacturing suite by year-end 2022 at the Princeton West Innovation Campus in Hopewell, N.J., for scale-up capability to support R&D pipeline as well as future development plans

07:51 EST Editas Medicine reports on recent progress, outlook on programs - Editas Medicine (EDIT) announced the company's recent progress and upcomning milestones. In Vivo Gene Edited Medicines Outlook: Editas Medicine completed dosing of all adult cohorts in its BRILLIANCE study of EDIT-101; the Company remains on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022; Additionally, the Company is expanding enrollment in one or more of the previously completed adult cohorts to support anticipated registrational trial design and endpoints; Editas also expects to provide a clinical update on the BRILLIANCE trial in the second half of 2022; The Company also anticipates establishing registrational trial criteria for EDIT-101 by year-end 2022; The Company is advancing additional in vivo ocular editing programs, leveraging its learnings from EDIT-101, and has declared a new development candidate, EDIT-103, for treatment of rhodopsin-associated autosomal dominant retinitis pigmentosa which is progressing towards IND-enabling studies; An optimized version of EDIT-102 for treatment of Usher syndrome 2A-associated retinitis pigmentosa is in lead optimization; The Company expects to declare an additional new development candidate for an in vivo ocular indication in 2022. Ex Vivo Gene Edited Medicines Outlook - The Company is developing EDIT-301 for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. The Phase 1/2 RUBY trial for the treatment of sickle cell disease is currently enrolling study participants and is on track to begin dosing in the first half of 2022 with initial clinical results expected by the end of 2022. The Company recently received clearance from the U.S. Food and Drug Administration of its investigational new drug application for EDIT-301 for the treatment of TDT, and expects to initiate dosing in a Phase 1/2 clinical study in TDT during 2022. Cellular Therapy Outlook: Editas Medicine has announced the development candidate EDIT-202. Editas Medicine expects to further optimize and advance this therapy in preclinical development during 2022. The ongoing collaboration between Editas Medicine and Bristol Myers Squibb (BMY) continues to advance alpha-beta T cell medicines for the treatment of solid and liquid tumors. Editas Medicine continues to evaluate the application of its iPSC platform to additional cell types beyond iNK and alpha-beta T cells. These include gamma-delta T cells for oncology indications and multiple cell types for regenerative medicine applications of iPSCs.

07:50 EST Orchard Therapeutics expects cash to fund requirements into 1H23 - The company ended 2021 with approximately $220 million of cash and investments. The company expects that its cash, cash equivalents and investments as of December 31, 2021 will support its currently anticipated operating and capital expenditure requirements into the first half of 2023. This cash runway excludes an additional $67 million that could become available under the company's credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers granted by the FDA following future U.S. approvals.

07:48 EST U.S. Energy announces closing of acquisitions - U.S. Energy announced the successful closing, on January 5, 2022, of the previously announced transactions to purchase certain oil and gas assets from Lubbock Energy Partners LLC, Synergy Offshore LLC, and certain entities controlled by Sage Road Capital. The Acquired Assets represent an operated portfolio of low decline, oil weighted assets across the Rockies, West Texas, Eagle Ford, and Mid-Continent. The acquisitions create a diversified, low leverage, free cash flow generating U.S. independent oil and natural gas company focused on continued consolidation. U.S. Energy issued an aggregate of 19,905,736 shares of common stock paid $1.25 million of cash, and assumed $3.5 million of indebtedness from the Sellers as part of the Transactions, equating to total consideration of $72.4 million. The issuance of the shares of common stock in connection with the Transactions was approved by the shareholders of the Company at the special meeting of shareholders held on January 4, 2022. As previously announced, Company management will be led by Ryan Smith who will continue to serve as Chief Executive Officer and as a member of the Board of Directors. John Weinzierl will serve as Chairman of the Board of Directors. As part of the transaction, the U.S. Energy Board of Directors increased from five to seven members, including Mr. Weinzierl as Chairman, Mr. Duane King, and Mr. Joshua Batchelor, and four legacy Directors from U.S. Energy, including Mr. Smith. Concurrent with the closing of the Transactions, the Company entered into a new four-year $100 million senior secured credit facility with an initial borrowing base of $15.0 million. The Company will initially have $3.5 million outstanding on the New Credit Facility, representing the assumed indebtedness from the Transactions. The New Credit Facility's opening effective interest rate is expected to be 3.75% per annum.

07:46 EST Theseus Pharmaceuticals: First patient treated with THE-630 - Theseus Pharmaceuticals announced that the first patient has been treated in the Phase 1 portion of Theseus' ongoing Phase 1/2 study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors. Data from the Phase 1/2 clinical trial is expected to inform further clinical development of THE-630 including the design of an initial registrational trial in fifth-line GIST, where there is currently no available therapy and therefore a significant unmet need. THE-630 is also expected to be evaluated in second-line GIST, where a pan-KIT inhibitor with activity against all major classes of activating, or cancer-causing, and resistance mutations has the potential to deliver meaningful clinical benefit over the current standard of care. Initial data from the Phase 1 portion of the clinical trial is expected to be presented at a scientific meeting in the first half of 2023.

07:46 EST Vaxxinity awarded grant from Michael J. Fox Foundation for UB-312 study - Vaxxinity has announced that the company has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research for the exploration of markers for target engagement in individuals with Parkinson's disease. Vaxxinity is developing its PD vaccine candidate UB-312, which has completed Part A of a first-in-human study in healthy volunteers and is advancing to Part B in Parkinson's patients. This award from MJFF will support the discovery and development of relevant pharmacodynamic markers. Specifically, the funds will be used to investigate whether Protein Misfolding Cyclic Amplification (PMCA) could be implemented as a robust method to assess target engagement in subjects immunized with UB-312. In recent years, PMCA has demonstrated excellent sensitivity and specificity for the detection of pathological forms of alpha-synuclein in the cerebrospinal fluid of PD patients and has been shown to discriminate accurately between those with synucleinopathies, including PD and Multiple System Atrophy, versus healthy individuals. UB-312 is designed to target pathological forms of aSyn for the treatment and prevention of synucleinopathies, including PD. UB-312 was selected as a clinical candidate through a comprehensive screening and profiling campaign, and demonstrated strong immunogenicity and efficacy in preclinical studies. In the healthy volunteer portion of a first-in-human Phase 1 trial, UB-312 was found to be generally well tolerated at multiple dose levels. Serum and CSF anti-aSyn antibody titers were dose-dependent and indicated that antibodies crossed the blood-brain barrier with a CSF:Serum ratio up to 0.2%. Vaxxinity plans to initiate Part B of the Phase 1 trial later this month to assess the safety, tolerability, and immunogenicity of UB-312 in PD patients. Vaxxinity's senior vice president of preclinical R&D, Jean-Cosme Dodart, PhD, will serve as principal investigator of the exploratory project funded by MJFF.

07:45 EST Viking Therapeutics initiates Phase clinical trial of VK2735 - Viking Therapeutics announced the initiation of a Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2735 is in development for the potential treatment of various metabolic disorders.

07:44 EST Kymera Therapeutics announces 2022 goals, milestones - Kymera Therapeutic announced its research and development goals and key milestones for 2022. 2022 Pipeline Objectives: Kymera is discovering and developing novel small molecule therapeutics designed to selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, with an initial focus on immune-inflammatory diseases and oncology. IRAK4 Degrader Program: In 2021, Kymera disclosed data from the single ascending dose and multiple ascending dose portions of its Phase 1 randomized, double-blind, placebo-controlled clinical trial in healthy volunteers. The MAD data demonstrated potent, marked IRAK4 reduction in peripheral blood mononuclear cells with steady-state degradation at Day 14 of 92% at the lowest dose level and 96-98% at the two highest dose levels, where IRAK4 was reduced to near the lower limit of quantitation of the assay. Proof of mechanism in the skin was established as mean IRAK4 levels were reduced to near the LLOQ by the final day of dosing on Day 14 at the highest dose level. The continued decline of IRAK4 in skin on Day 14 in the 50-200 mg cohorts suggested that steady-state degradation in skin had not yet been achieved. Proof-of-biology was demonstrated through inhibition of up to 9 disease relevant cytokines with the 100 mg dose reaching 85% inhibition. KT-474 multi-dosing was safe and well-tolerated. Kymera has now completed dose escalation in the SAD and MAD healthy volunteer portions of KT-474's Phase 1 clinical trial and will review all clinical data prior to initiating the open-label patient portion of the study. Expected 2022 Milestones: Commence patient dosing of Phase 1 trial; Present data from patient cohort showing proof of mechanism and proof of biology; Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 , outside of the oncology and immune-oncology fields. IRAKIMiD Degrader Program: In 4Q21, Kymera announced IND clearance of KT-413, the company's potent degrader of IRAK4 and IMiD substrates. KT-413's Phase 1 trial will evaluate safety, PK/PD, and preliminary efficacy in MYD88 mutant and MYD88 wild-type relapsed/refractory Diffuse Large B-Cell Lymphoma. Primary study endpoints will include safety, tolerability and recommended Phase 2 dose, with secondary endpoints of PK and preliminary efficacy. The trial will also explore target knockdown and downstream effects in PBMC and tumors. Expected 2022 Milestones: Present first proof of mechanism clinical data to de-risk further development; Present new preclinical data to enable indication expansions in new oncology indications. STAT3 Degrader Program: In 4Q21, Kymera announced IND clearance of KT-433, the company's potent degrader of STAT3. KT-333's Phase 1 trial will evaluate safety, PK/PD, and preliminary efficacy in peripheral T cell lymphoma, cutaneous T cell lymphoma, large granular lymphocytic leukemia and solid tumors. Primary study endpoints will include safety, tolerability and recommended Phase 2 dose, with secondary endpoints of PK and preliminary efficacy. The trial will also explore STAT3 knockdown and downstream effects in PBMC and tumors. Expected 2022 Milestones: Present first proof of mechanism clinical data to de-risk further development; Present new preclinical data to enable indication expansions in new oncology indications; Present new preclinical data to demonstrate relevance of STAT3 degradation in immunology and fibrosis. MDM2 Degrader Program: At last month's R&D Day, Kymera announced its new development program and development candidate, KT-253, a potent and selective degrader of MDM2 with potential to be a best-in-class P53 stabilizer. Degradation of MDM2, rather than inhibition, has the ability to block the feedback loop which up-regulates MDM2 production and in doing so more effectively drives tumor cells to rapid apoptosis. KT-253 inhibits tumor cell growth with picomolar potency that is more than 200-fold greater than clinically active MDM2 small molecule inhibitors. This leads to sustained tumor regression in vivo in leukemia models following just a single dose. As wild-type p53 is present in greater than50% of tumors, KT-253 represents another program with broad franchise potential in liquid and solid tumors. Kymera is focused on indications with specific sensitivity to this mechanism of action, such as AML, lymphomas, uveal melanoma and others through a focused biomarker strategy. Expected 2022 Milestones: Present additional preclinical data that outline the biomarker strategy as well as new indications for KT-253;File IND for KT-253; Discovery and Platform. Kymera is also actively advancing a broad pipeline of preclinical programs across a wide variety of diseases, both internally and in collaboration with existing partners Vertex Pharmaceuticals and Sanofi. The internal programs continue to be focused on undrugged or inadequately drugged nodes within highly validated pathways. Kymera is committed to drugging all high value target classes in human cells in a technology- and disease-agnostic manner with particular focus on using tissue-selective or -restricted E3 ligase and molecular glue degraders where needed to elicit the best clinical response. Key 2022 Objectives: Nominate first Development Candidate using a tissue restricted E3 ligase; Continue pipeline expansion by advancing early-stage discovery programs toward IND-enabling studies; Further expand the capabilities of Kymera's Pegasus platform to identify the optimal pairing of disease-causing protein targets with E3 ligases to generate novel degrader product candidates; Leverage Kymera's E3 Ligase Whole-Body Atlas of over 600 unique E3 ligases to identify previously unliganded E3 ligases, including tissue-restricted or -selective, as well as new small molecule molecular glue degraders to unlock new opportunities across broad therapeutic applications. 2022 Corporate Objectives: Kymera's mission is to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation. The Company's goal is to become a fully integrated biopharmaceutical company with a pipeline of novel medicines targeting disease-causing proteins that were previously intractable. In 2022, Kymera plans to continue to grow and strengthen its organizational capabilities in order to deliver on the potential of inventing a new class of protein degrader medicines for patients.

07:43 EST Anavex reports results from Phase 1 trial of ANAVEX 3-71 - Anavex Life Sciences announced "positive" top-line results from its Phase 1 clinical trial of ANAVEX 3-71, an oral small molecule agonist of both SIGMAR1 and CHRM1 in development for the treatment of neurodegenerative diseases including Frontotemporal Dementia, FTD, for which ANAVEX 3-71 has been granted Orphan Drug Designation, ODD, by the FDA. The study was a double-blind, randomized, placebo-controlled, Phase 1 trial to evaluate safety and tolerability, and pharmacokinetics of oral escalating doses of ANAVEX 3-71 including effects of food and gender in healthy volunteers. ANAVEX(R)3-71 was well tolerated in all cohorts receiving ANAVEX 3-71 in single doses ranging from 5 mg to 200 mg daily with no serious adverse events, SAEs, and no significant lab abnormalities in any subject. In the study, ANAVEX 3-71 exhibited linear pharmacokinetics. Gender had no effect on the PK of the drug and food had no effect on the bioavailability of ANAVEX(R)3-71. The study also met the secondary objective of characterizing the effect of ANAVEX 3-71 on electrocardiogram, ECG, parameters. There were no clinically significant ECG parameters throughout the study. Based on these results, and ANAVEX 3-71 pre-clinical profile, the Company intends to advance ANAVEX 3-71 into a biomarker-driven clinical development dementia program for the treatment of FTD, schizophrenias and Alzheimer's disease, evaluating longitudinal effect of treatment with ANAVEX 3-71 initiating in 2022.

07:40 EST Fulcrum Therapeutics expects cash to fund requirements into 2024 - As of December 31, 2021, Fulcrum's cash, cash equivalents and marketable securities were $218.2 million. Based on its current operating plans, the company believes this is sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2024.

07:39 EST Fulcrum Therapeutics announces upcoming milesones - Fulcrum Therapeutics outlined its recent accomplishments and expected upcoming milestones. Fulcrum will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 12:00 p.m. ET."Fulcrum made substantial progress in 2021, positioning us for a transformative 2022," said Bryan Stuart, president and chief executive officer. "Our clinical results with losmapimod highlight its potential to slow or stop the progression of FSHD, a relentless form of muscular dystrophy that leads to loss of upper body function and mobility and for which there are no treatments. We also reported results from our clinical program with FTX-6058, supporting its potential to be a functional cure for sickle cell disease. Based on these results, we are intently focused on advancing this oral HbF inducer for people with sickle cell disease as well as other hemoglobinopathies. As we enter 2022, we are building on this progress, with multiple milestones expected across our clinical and discovery-stage pipeline," Mr. Stuart continued. "We plan to provide an update on losmapimod in the first quarter. I'm also pleased to share that we enrolled the first patient with sickle cell disease in our Phase 1b trial, putting us on track to report initial data in the second quarter of 2022. We also submitted an IND for FTX-6058 in select hemoglobinopathies and expect to start a Phase 1b trial in the second quarter of 2022. In parallel, we continue to advance our FulcrumSeek product engine and plan to nominate our next development candidate this year to support an IND by the end of the first quarter of 2023." Recent Accomplishments: Dosed first sickle cell disease patient in the Phase 1b clinical trial of FTX-6058, an oral fetal hemoglobin inducer. Completed three-month preclinical toxicology studies and initiated chronic toxicology studies to advance FTX-6058 in multiple indications. Submitted Investigational New Drug application to initiate clinical development of FTX-6058 in select hemoglobinopathies, including beta-thalassemia. Announced the appointment of Esther Rajavelu as Chief Financial Officer. Expected Milestones: Losmapimod: Provide an update in the first quarter of 2022 on plans for a Phase 3 clinical trial of losmapimod in facioscapulohumeral muscular dystrophy. FTX-6058: Report initial data, including measures of HbF protein induction, from the Phase 1b trial in people with sickle cell disease in the second quarter of 2022. Initiate Phase 1b trial in select hemoglobinopathies, including beta-thalassemia, in the second quarter of 2022. Initiate registrational trial in sickle cell disease in early 2023. Preclinical Pipeline: Nominate next development candidate by end of 2022 to support the company's fourth IND by the end of the first quarter of 2023.

07:38 EST Surgery Partners appoints David Doherty as Chief Financial Officer - The Company announced that David Doherty, Senior Vice President, Corporate Finance and Controller at Surgery Partners, will assume the role of Chief Financial Officer, effective February 1, 2022. Tom Cowhey will be transitioning from his role as Chief Financial Officer to pursue a new opportunity. To ensure a smooth transition, Cowhey has agreed to remain with the Company through the end of February.

07:36 EST EyePoint names Michael Pine as chief corporate development, strategy officer - EyePoint Pharmaceuticals announced the appointment of Michael Pine as Chief Corporate Development and Strategy Officer. Most recently, Mr. Pine was a Senior Vice President of Business Development and Strategy at Medexus Pharmaceuticals, where he identified, evaluated and executed several transactions critical to the growth of the organization. In connection with the hiring of Mr. Pine, the Compensation Committee of Eyepoint Pharmaceutical's Board of Directors granted stock options to purchase an aggregate of 100,000 shares of common stock as an inducement award material to Mr. Pine entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to the closing price of EyePoint's common stock on January 10, 2022, and will vest as follows: 25% on the first anniversary and monthly through the fourth anniversary of the date of grant, subject to the terms of grant.

07:35 EST Jazz Pharmaceuticals announces $5B revenue target for 2025 - Jazz Pharmaceuticals announced its Vision 2025 to deliver sustainable growth and enhanced value. Vision 2025 includes the following expectations: 1) generating $5B in revenue in 2025; 2) approval of at least five additional novel products by the end of the decade; and 3) realizing a 5% adjusted operating margin improvement from 2021 to 2025, driven by operational excellence. The company also confirmed that it expects to meet its previously announced 2021 revenue guidance range of $3.02B-$3.1B and its net product sales guidance for neuroscience and oncology. Jazz ended 2021 demonstrating executional excellence across its business, including launching five key products in 2020 and 2021, integrating the GW Pharmaceuticals business, making progress towards its deleveraging target and initiating multiple potentially registrational clinical trials. The company remains on track to deliver revenue diversification, with at least 65% of 2022 net product revenue from newly launched or acquired products, driving sustainable growth and enhanced shareholder value. "Building on our track record of strong execution and guided by our patient-centric approach, Jazz is setting forth its Vision 2025 to deliver meaningful treatment options to patients, a great place to work for employees and significant value to shareholders," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals. "Jazz's leadership in sleep and rare epilepsy with Xywav and Epidiolex, respectively, coupled with promising new oncology products like Zepzelca and Rylaze, have led to the rapid transformation of our revenue base. We are further poised to enter new disease areas with serious unmet patient need and substantial market potential, including movement disorders and PTSD, with our mid-to late-stage assets nabiximols, suvecaltamide and JZP150. We expect our continued operational excellence to drive a five-percentage point improvement in our adjusted operating margin from 2021 to 2025, and we are confident in our ability to continue to leverage strategic capital allocation to grow our business."

07:28 EST Karyopharm names Sohanya Cheng as Chief Commercial Officer - Karyopharm Therapeutics (KPTI) announced that Sohanya Cheng has been promoted to Chief Commercial Officer. She will be responsible for leading the company's commercial strategy and operations, including the continued commercialization of XPOVIO. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations. Prior to joining Karyopharm, she served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals (ARWR).

07:27 EST Replimune Group provides anticipated milestones for 2022 - Replimune Group provided a corporate update, highlighting the progress of key programs. Anticipated Key Milestones for 2022: CERPASS - Registration-directed Phase 2 clinical trial in cutaneous squamous cell carcinoma: The Company is actively enrolling patients in a Phase 2 clinical trial evaluating RP1 in combination with Libtayo vs. Libtayo alone in patients with advanced CSCC. The Company expects to complete enrollment such that the trigger for the primary data analysis is expected in late 2022. IGNYTE - Multi-cohort Phase 2 clinical trial of RP1 combined with Opdivo: Anti-PD-1 failed melanoma cohort: The Company continues to enroll patients in the IGNYTE Phase 2 clinical trial. The company expects to release interim data from this cohort in late 2022. Non-melanoma skin cancer cohort: The Company remains on track to provide updated data from the anti-PD1 naive patients and initial data from the anti-PD-1 failed patients in the first quarter of 2022. Anti-PD-1 failed non-small cell lung cancer cohort: Enrollment is open, with initial data is expected to be released in late 2022. ARTACUS - Phase 1b/2 clinical trial of RP1 as monotherapy in solid organ transplant recipients with CSCC: Enrollment continues in this trial. The Company remains on track to present initial data from this clinical trial in the first quarter of 2022. RP2 and RP3 : RP2 alone and in combination with Opdivo in difficult-to-treat cancers: The Company initiated its expansion of the Phase 1 clinical trial of RP2 in combination with Opdivo. The company expects to present initial data from the expansion patients in late 2022. RP3 alone and in combination with Opdivo: The Company is enrolling patients in a Phase 1 clinical trial for RP3, with initial data expected to be presented in the first quarter of 2022. The company expects to present initial data from the expansion patients in late 2022. RP2 and/or RP3 next stage development including in patients with liver metastases from a range of tumor types: The Company remains on track to initiate a broad clinical development program with RP2 and/or RP3 around mid-year 2022.

07:26 EST Omega Therapeutics names Yan Moore, M.D., as Chief Medical Officer - Omega Therapeutics announced the appointment of Yan Moore, M.D., as Chief Medical Officer. Dr. Moore has extensive management, research, translational drug development and medical affairs experience across various pharmaceutical and biotechnology companies. Dr. Moore most recently served as Senior Vice President, Head of Oncology Therapeutic Area at Ipsen Pharmaceuticals where he focused on scientific and development strategy as well as identifying and executing on research and development objectives in the areas of oncology and immune-modulatory therapies.

07:24 EST Clarivate names Gordon Samson as Chief Product Officer - Clarivate announced that as part of its One Clarivate Vision to put even greater focus on its customers and solutions, effective February 1, Gordon Samson will become Chief Product Officer. Samson, who is currently President of the IP Segment, will support the four Clarivate customer verticals in this newly created and focused role. With this change, Mukhtar Ahmed, President of the Science Segment, will be leaving the company. Ahmed will work with Samson on the transition of the Science team and the ProQuest integration until April 1, 2022, then will remain in an advisory role to the company until his departure on October 1, 2022.

07:23 EST Amicus provides updates, anticipated milestones by program - Amicus Therapeutics provided its corporate updates, and full-year 2022 outlook. Updates and Anticipated Milestones by Program: Galafold Oral Precision Medicine for Fabry Disease: Sustain double-digit revenue growth in 2022 of $350M-$365M; Continue geographic expansion; and Registry and other Phase 4 studies ongoing. AT-GAA for Pompe Disease: U.S. Prescription Drug User Fee Act action date of May 29, 2022 for the NDA and July 29, 2022 for the BLA; EU Committee for Medicinal Products for Human Use opinion expected in late 2022; Continue to broaden access through early access plans in the U.K., Germany, Japan, and other countries; and Ongoing supportive studies, including pediatric and extension studies. Gene Therapy Pipeline: Advance IND-enabling studies, manufacturing activities, and regulatory activities for the Fabry disease gene therapy program towards an anticipated IND in 2023; Progress preclinical studies, manufacturing activities, and regulatory activities for the Pompe disease gene therapy program; Discontinue CLN6 Batten disease gene therapy program following review of long-term extension study data. It was recently determined that any initial stabilization of disease progression at the two-year time point was not maintained through the long-term extension study; Advance CLN3 Batten disease program with the higher dose, different promoter, and intra-cisterna magna route of delivery pending further Phase 1/2 clinical data and pre-clinical data expected in 2022. These data will inform timeline for commencement of any pivotal clinical study

07:18 EST Tilray reports synergies from Aphria combination $70M on run-rate basis to date - Cost synergies from Aphria-Tilray combination of $70 million achieved on a run-rate basis to date, with actual cash-savings close to $36 million to date. Expect to reach $80 million synergy target, ahead of schedule, by May 31, 2022 and to generate an additional $20 million in synergies in fiscal 2023.

07:17 EST Karyopharm sees Q4 net product revenues of XPOVIO $29.7M - Karyopharm Therapeutics announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the company's first-in-class, oral XPO1 inhibitor. Based on preliminary unaudited financial information, Karyopharm expects net product revenues of XPOVIO to be approximately $29.7M for the fourth quarter and approximately $98.3M for the full year 2021. Q4/FY21 revenue consensus is $30.88M/$114.03M, respectively. "For 2022, we are focused on making significant advances across our pipeline, beginning with top-line results from the Phase 3 SIENDO study evaluating selinexor as a maintenance therapy following front-line chemotherapy in patients with advanced or metastatic endometrial cancer, which remain on track to be reported this quarter," said Richard Paulson, President and CEO of Karyopharm. "Building on the strong revenue growth in the second half of 2021, we will continue to prioritize driving sales and the adoption of XPOVIO in multiple myeloma. I am extremely pleased with the continued progress of our pipeline in key additional indications of multiple myeloma, myelodysplastic syndromes and myelofibrosis and our ability to further expand our impact on patients globally with our recent partnership with Menarini."

07:15 EST F45 Training sees Q4 SSS up 6% globally, up 53% in U.S. - Preliminary expected results for Q4: Same store sales increased by 6% globally and 53% in the United States. System-wide sales increased by 27% globally and 95% in the United States. System-wide visits increased by 7% globally and 50% in the United States. Net new studio openings totaled approximately 130 compared to 61 in the prior year period. Net new franchises sold totaled approximately 275 compared to 30 in the prior year period.

07:12 EST Discovery Inc. to become minority owner of OpenAP - OpenAP and Discovery (DISCA, DISCB) announced that Discovery will become a minority owner of OpenAP, the advanced advertising company bringing simplicity and scale to audience-based campaigns in television. Discovery joins FOX (FOX, FOXA), NBCUniversal and ViacomCBS (VIAC) in the joint venture. The investment signals an expansion of Discovery's existing relationship with OpenAP, having integrated with the central TV identity spine, OpenID, in April 2021 and more recently partnering with OpenAP on the launch of XPm, the TV publisher backed cross-platform measurement framework. The commitment to OpenAP furthers Discovery's strategy of building a technical framework that enables cross-platform audience-based buying and creating collaborative support for alternative currency standards. For OpenAP, it will help further its ability to grow the overall market for audience-based advertising and expand the breadth and scale of its services across cross-platform identity, measurement and planning.

07:12 EST BioCryst says BCX9930 pivotal trials in PHN now enrolling - BioCryst is currently enrolling patients in two global pivotal trials, REDEEM-1 and REDEEM-2, with the company's oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria. The company also has begun screening patients in a proof of concept basket trial of BCX9930 (500 mg bid) in patients with C3 glomerulopathy, IgA nephropathy and primary membranous nephropathy (PMN). BioCryst plans to further advance and expand its Factor D program over the next two years by achieving the following: Complete and report data from REDEEM-1 and REDEEM-2 Prepare to submit regulatory approval filings in PNH Complete the renal PoC basket trial and advance to pivotal trials in C3G, IgAN and PMN Commence PoC trials in other complement-mediated diseases "Following the discovery, development and commercialization of ORLADEYO, the BioCryst team plans to repeat this success as we leverage our platform to bring new oral medicines to patients suffering from other rare diseases. BCX9930 is especially exciting because the clinical data we have reported so far provides confidence that we can help patients in PNH, and across many complement-mediated diseases, with this pipeline in a molecule," said Dr. Helen Thackray, chief research and development officer of BioCryst.

07:09 EST Gatos Q4 silver production up 35% to 2.3M ounces in Q4 from Q3 - Gatos Silver is very pleased to report record silver production and plant throughput from the 70%-owned Cerro Los Gatos mine during the fourth quarter of 2021 . Silver production in Q4 was 2.3 million ounces and increased 35% compared to the Q3, due primarily to higher mined silver ore grades as well as higher throughput and recoveries. Lead and zinc production in Q4 were slightly below Q3 levels, due to lower mined lead and zinc ore grades. CLG's 2021 silver production of 7.6M ounces exceeded the Company's guidance of 7.4 million ounces. Zinc and lead production of 50 million and 40M pounds, respectively, were both consistent with the Company's 2021 guidance range. CLG achieved record throughput in Q4 totaling 241,397 tonnes, exceeding Q3 throughput by 3.1%. For 2021, 909,586 tonnes were processed, a 36% increase compared to 2020, which included a 45-day pandemic-related temporary suspension of plant operations. CLG achieved record silver recovery during Q4, with recoveries for silver, lead and zinc continuing to exceed design rates. Due to record 2021 production, and elimination of debt service requirements by the early retirement of the Los Gatos Joint Venture Working Capital Facility and Term Loan during 2021, the LGJV had over $20 million of cash at December 31.

07:06 EST Enterprise Products to acquire Navitas Midstream Partners for $3.25B - Enterprise Products announced that its affiliate has entered into a definitive agreement to acquire Navitas Midstream Partners from an affiliate of Warburg Pincus in a debt-free transaction for $3.25B in cash consideration. Navitas Midstream provides natural gas gathering, treating and processing services in the core of the Midland Basin of the Permian. Navitas Midstream's assets include approximately 1,750 miles of pipelines and over 1B cubic feet per day of cryogenic natural gas processing capacity with the completion of the Leiker plant, which is expected in the first quarter of 2022. This acquisition provides Enterprise's natural gas processing and NGL business with an entry point into the Midland Basin, one of the most economic and prolific crude oil regions in the United States. Drilling activity in the Midland Basin currently represents approximately 20% of active onshore drilling rigs in the U.S. The system is anchored by long-term contracts and acreage dedications with a diverse group of over forty independent and publicly owned producers. Navitas Midstream provides visibility to future growth with up to 10,000 drilling locations, or over fifteen years of drilling inventory based on current rig counts, on the dedicated acreage. The system is supported by fee-based contracts that provide additional revenues based on commodity prices. This transaction is expected to be completed in the first quarter of 2022 subject to customary regulatory approvals. The transaction is expected to be funded using cash on hand and borrowings under the partnership's existing commercial paper and bank credit facilities. "The system, including its large footprint of low pressure natural gas gathering, is an attractive processing franchise that provides value added services to producers," stated Randy Fowler, co-chief executive officer and chief financial officer of Enterprise's general partner. "We believe this acquisition will be immediately accretive to distributable cash flow per unit. Based on the current outlook for commodity prices in 2023, which would be our first full year of ownership, we believe distributable cash flow accretion will be in the range of $0.18 to $0.22 per unit. This investment will provide Enterprise with an attractive return on capital and support additional capital returns to our limited partners through distribution growth and buybacks of common units."

07:05 EST Origin, Mitsui team to industrialize advanced carbon-negative materials - Origin Materials and Mitsui & Co announced a strategic partnership to industrialize advanced carbon negative materials. This strategic partnership aims to rapidly develop and industrialize new sustainable carbon-negative products for the automotive, chemicals, electronics, packaging, textiles, construction, and personal care industries based on Origin Materials' patented technology platform. The partnership will leverage Mitsui's global supply chain strength, access to Japanese and international markets, and leadership in business innovation. As part of the partnership, Mitsui signed a multi-year capacity reservation agreement to purchase sustainable carbon-negative materials from Origin Materials. "We are pleased to partner with Mitsui, a global leader in multiple business areas, including chemicals, textiles, and many others. We are strategically aligned and share a common vision for the role that sustainable, cost-competitive, carbon-negative materials can play in creating value worldwide," said Rich Riley, Co-CEO of Origin Materials. "This partnership reflects our shared commitment to driving sustainable growth, while reducing greenhouse gas emissions. Additionally, the partnership represents further progress in Origin's mission to enable the world's transition to sustainable materials."

06:59 EST Commercial Metals announces plan to construct micro mill - Commercial Metals announced a plan to construct another micro mill geographically situated to primarily serve the Northeast, Mid-Atlantic, and Mid-Western United States markets. CMC believes that the location and capabilities of the planned facility will significantly augment CMC's scale in the Eastern U.S. and synergistically complement its existing operational footprint. CMC is currently in the site selection process and exploring several suitable options. The new micro mill will be among the most environmentally friendly steelmaking operations in the world. The technology to be employed is lower in both energy consumption and greenhouse gas emissions compared to traditional steelmaking processes. Following receipt of state and local incentives, permitting, and other necessary approvals, the construction of the planned mill is expected to take roughly two years.

06:55 EST Codex DNA signs collaboration and licensing agreement with Pfizer - Codex DNA (DNAY) announced a strategic collaboration and licensing agreement with Pfizer (PFE) to access and further develop Codex DNA's novel EDS technology for potential application by Pfizer for its mRNA-based vaccines and other biopharma products. The financial terms of the deal include an upfront payment from Pfizer to Codex DNA, along with success-based technical milestone payments that could be earned in the near term. Codex DNA is also eligible to receive additional milestone payments based on the achievement of specified development, regulatory, and commercialization goals associated with any products developed from the application of Codex DNA's technology developed and licensed under the agreement. Pfizer's successful development and commercialization of licensed products could result in milestone payments in excess of $100M.

06:54 EST Genesco reports Q4 QTD sales up 18% - Reports Q4 QTD sales up 9% vs FY20. Mimi Vaughn, Genesco board chair, president and chief executive officer, said, "We are pleased with our performance this holiday selling season, especially given the supply chain challenges, as strong full-priced selling drove better than expected sales and profitability. While traffic levels have remained healthy thus far in January, our sales trend has moderated as inventory is currently very lean; however, we expect our in-stock positions to improve as the month progresses and feel confident that we will finish the year strong. Therefore, we are reaffirming our total year EPS guidance of $6.40 to $6.90, with our expectation now above the midpoint of the range."

06:50 EST BHP Group to invest $40M in Kabanga Nickel, $10M in Lifezone - Kabanga Nickel announces that BHP has invested $40M in Kabanga Nickel. The money will be used to accelerate the construction of the Kabanga Nickel Project in Tanzania. In parallel, BHP has invested $10M in Lifezone Limited to promote the distribution of its patented technology in hydrometallurgy. The transaction is a total of $50M, including investments in Kabanga Nickel and Lifezone. BHP will invest $90M in unsecured convertible securities within Kabanga Nickel in two phases: An initial investment of $40M, followed by another investment of $50M after the agreement was reached and the terms of the agreement were fulfilled. After completing all legal formalities in Tanzania, the first Phase of $40M will be converted to 8.9% of Kabanga Nickel shares. After being invested and converted into shares, the second installment of $50M will increase BHP shares in the KNL to 17.8%, bringing the project value to $658M. Upon completion of other terms, BHP will be entitled to make further investments in Kabanga Nickel after reaching the agreed criteria. Investment from BHP at Kabanga Nickel will help speed up the construction of the mine. Other activities that will be given priority are relocation of people from the mine area, preliminary preparations for the construction of the mine including the construction of mine roads, staff housing area, construction of water wells and electrical infrastructure. Investment in the Lifezone company allows for new patent applications, in addition to the existing 100 copyright holders, as well as the Research and Development work that will further assist in promoting the hydromet technology market from Lifezone. The current project construction schedule expects production to begin in 2025. Production will increase to a production target of 40,000 tons of nickel, 6,000 tons of copper and 3,000 tons of cobalt per year.

06:48 EST Merck's Keytruda shows significant improvement in IB-IIIA NSCLC in phase 3 data - The company states: "Merck announced that the Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 - PEARLS, investigating KEYTRUDA, Merck's anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer, or NSCLC, following surgical resection regardless of PD-L1 expression. Based on an interim analysis review conducted by an independent Data Monitoring Committee, adjuvant treatment with KEYTRUDA resulted in a statistically significant and clinically meaningful improvement in DFS compared with placebo in the all-comer population of patients with stage IB-IIIA NSCLC. At the interim analysis, there was also an improvement in DFS for patients whose tumors express PD-L1 treated with KEYTRUDA compared to placebo; however, this dual primary endpoint did not meet statistical significance per the pre-specified statistical plan. The trial will continue to analyze DFS in patients whose tumors express high levels of PD-L1 and evaluate overall survival, a key secondary endpoint. The safety profile of KEYTRUDA in this study was consistent with that observed in previously reported studies. Results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities."

06:44 EST Air Lease announces Q4 activity update - Air Lease (AL) announced an update on aircraft investments, sales, and new significant financing occurring in the fourth quarter of 2021. As of December 31, 2021, ALC's fleet was comprised of 382 owned aircraft and 92 managed aircraft, with 416 new aircraft on order from Boeing (BA) and Airbus (EADSY) set to deliver through 2028. Delivered fifteen new aircraft from ALC's order book including seven Airbus A321neos, three Airbus A350-1000s, one Boeing 737-8, and four Boeing 737-9s. Aircraft investments in the quarter totaled approximately $1.2B, with the majority occurring in the second half of the quarter. Sold three aircraft to third-party buyers. Issued $300M of 4.125% fixed-rate reset non-cumulative perpetual series C preferred stock. Upsized senior unsecured revolving credit facility to $6.8B from $6.5B.

06:36 EST Tilly's reports holiday period net sales $173.3M, SSS up 14.1% - Tilly's announced net sales results for the nine-week period ended January 1, 2022 in advance of its virtual participation in the ICR Conference 2022 on January 10-12, 2022. Total net sales of $173.3M increased by 16.5% for the 2021 holiday period compared to $148.7M for last year's comparable nine-week holiday period ended January 2, 2021. Total comparable net sales, including both physical stores and e-commerce, increased by 14.1% for the 2021 holiday period compared to an increase of 2.7% for the 2020 holiday period. Comparable net sales in physical stores increased by 23.2% for the 2021 holiday period compared to a decrease of 12.4% during the 2020 holiday period. Comparable net sales in physical stores increased by a double-digit percentage in all but one of 14 geographic markets compared to the 2020 holiday period. Net sales in physical stores represented 74.5% of total net sales for the 2021 holiday period compared to 68.4% of total net sales during the 2020 holiday period. E-commerce net sales decreased by 5.7% for the 2021 holiday period compared to an increase of 65.2% during the 2020 holiday period. E-commerce net sales represented 25.5% of total net sales for the 2021 holiday period compared to 31.6% of total net sales during the 2020 holiday period. Compared to the 2019 holiday period, e-commerce net sales increased by 57.4%. The company believes these results were driven by favorable market conditions, a compelling merchandise assortment, and a shift in our customers' preference for shopping in physical stores over e-commerce compared to last year's holiday period. Last year, the impacts of the COVID-19 pandemic, including government-mandated restrictions on customer traffic in physical stores and reductions in store operating hours in effect during the 2020 holiday period, resulted in increased online shopping relative to physical stores compared to previous years. "Based on our strong 2021 holiday period results, we expect to report our most profitable fourth quarter since becoming a public company and our most profitable full fiscal year on record," commented Ed Thomas, President and CEO.

06:31 EST Pfizer partners with Acuitas Therapeutics on LNP delivery systems - Pfizer and Acuitas Therapeutics, a company focused on developing lipid nanoparticle delivery systems to enable messenger RNA-based therapeutics, announced they have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.

06:16 EST ALX Oncology announces anticipated milestones in 2022 - Anticipated milestones in 2022 include: Initiation of a randomized Phase 2/3 clinical trial of evorpacept in combination with Herceptin, Cyramza and paclitaxel in patients with 2nd line or greater gastric/GEJ cancer. Dose optimization readout of a Phase 1b clinical trial of evorpacept in combination with azacitidine in patients with MDS. Add to and report on investigator sponsored clinical trials with evorpacept. Report on ongoing collaboration with Zymeworks in HER2-expressing breast cancer and other solid tumors. Select development candidate(s) from preclinical pipeline. ALX Oncology ended the third quarter of 2021 with approximately $385.1M in cash and cash equivalents. The company expects that its cash and cash equivalents will be sufficient to fund its planned operations through mid-2024.

06:10 EST Theravance Biopharma enrolls first patient in Yupelri inhalation solution study - Theravance Biopharma announced enrollment of the first patient in a Phase 4 study of Yupelri inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the U.S. for the maintenance treatment of patients with chronic obstructive pulmonary disease, or COPD. Success in this study is intended to capture more of Yupelri's addressable market and further strengthen its competitive advantage.

06:05 EST R1 RCM to acquire Cloudmed for $4.1B - R1 RCM announced that it has entered into a definitive agreement to acquire Cloudmed, a leader in Revenue Intelligence solutions for healthcare providers, in an all-stock transaction. The transaction values Cloudmed at approximately $4.1B, including $857M of net debt, based on R1's closing stock price on January 7, 2022. The transaction is expected to be accretive to R1's earnings per share in the first full year post-closing. R1 expects to unlock cost synergies of $85M by the end of year three and $98M at full run-rate, as well as significant revenue synergies over time. R1 expects to have approximately 2.7x net leverage upon closing of the transaction and anticipates strong cash flow generation post-close. Upon closing of the transaction, current R1 shareholders will own approximately 70% of the combined company on a fully diluted basis and Cloudmed equity holders will own approximately 30%. Cloudmed equity holders will enter into an 18-month lockup agreement, subject to partial early release after six months under certain circumstances. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2022, subject to approval of the stock issuance by R1 shareholders, the effectiveness of a registration statement on Form S-4, receipt of regulatory approvals and the satisfaction of other customary closing conditions. Joe Flanagan, CEO of R1, will serve as CEO of the combined company, and Lee Rivas, CEO of Cloudmed, will serve as president of the combined company. Upon closing of the transaction, R1 will increase the size of its Board of Directors to include three new board members nominated by New Mountain Capital.

06:03 EST Pfizer, Beam Therapeutics announce four-year research collaboration - Pfizer (PFE) and Beam Therapeutics (BEAM) announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. The base editing programs to be evaluated as part of the collaboration will leverage Beam's proprietary in vivo delivery technologies, which use messenger RNA and lipid nanoparticles to deliver base editors to target organs. Combining these technologies with Pfizer's proven experience in developing and manufacturing medicines and vaccines, this collaboration seeks to advance potentially transformative therapies for patients living with rare diseases. Under the terms of the collaboration agreement, Beam will conduct all research activities through development candidate selection for three undisclosed targets, which are not included in Beam's existing programs. Pfizer may opt in to exclusive, worldwide licenses to each development candidate, after which it will be responsible for all development activities, as well as potential regulatory approvals and commercialization, for each such candidate. Beam has a right to opt in, at the end of Phase 1/2 studies, upon the payment of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which Pfizer and Beam would share net profits as well as development and commercialization costs in a 65%/35% ratio (Pfizer/Beam). Beam will receive an upfront payment of $300M and, assuming Pfizer exercises its opt-in license rights for all three targets, is eligible for development, regulatory and commercial milestone payments for potential total deal consideration of up to $1.35B. Beam is also eligible to receive royalties on global net sales for each licensed program. The collaboration has an initial term of four years and may be extended up to one additional year.

05:59 EST Humanigen outlines next steps for lenzilumab - Humanigen outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma, or rrNHL. FDA Type C meeting and advice creates alignment on registration pathway for Phase 3 clinical development of lenzilumab for the prevention of CAR-T therapy related toxicities including Immune Effector Cell-Associated Neurotoxicity and Cytokine Release Syndrome, or CRS. Randomized, double-blind, placebo-controlled SHIELD trial to commence in H1 2022, designed to inform a potential label that reflects both the clinical benefit of lenzilumab and the economic benefit. The SHIELD study will begin recruitment in H1 2022, with preliminary data potentially being shared at the American Society of Hematology congress in December 2022.

05:37 EST Amgen receives EC marketing authorization for Lumykras - Amgen announced that the European Commission, or EC, has granted conditional marketing authorization for Lumykras, a first-in-class KRASG12C inhibitor, for the treatment of adults with advanced non-small cell lung cancer with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

05:32 EST Molecular Partners, Novartis report Part A of EMPATHY trial met primary endpoint - Molecular Partners (MOLN) and Novartis (NVS) announced that Part A of the EMPATHY clinical trial, that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed clinically meaningful benefit over placebo composite endpoint of hospitalization and/or Emergency Room, or ER, visits or death, and time to sustained clinical recovery. Novartis confirms it will now exercise its option to in-license ensovibep from Molecular Partners and, following exercise of the option, will seek expedited access globally, first via the FDA's EUA process. The global EMPATHY clinical trial, which is being conducted by Novartis, with Molecular Partners as sponsor, is a randomized, double-blind, placebo controlled study in ambulatory adult patients with COVID-19. EMPATHY Part A enrolled 407 patients to identify a dose of ensovibep with optimal safety and efficacy and recruited patients in the USA, South Africa, India, the Netherlands, and Hungary to explore three doses: 75mg, 225mg and 600mg. Results from the study showed that the primary endpoint was met with a statistically significant reduction in viral load over eight days, compared to placebo, for all three dosing arms. The secondary endpoint of hospitalization and/or ER visits related to COVID-19, or death showed an overall 78% reduction in risk of events across ensovibep arms compared to placebo. Treatment arms were generally balanced in terms of demographic, baseline and disease characteristics. The placebo arm with 99 patients had a total of six events; five patients were hospitalized, two of whom died due to worsening of COVID-19 and one patient had an ER visit only. In the 301 patients treated with ensovibep, there were four events; hospitalizations occurred in two patients and two needed to visit ER. No deaths occurred in any of the patients treated with ensovibep. All doses were well-tolerated and no unexpected safety issues were identified for any of the doses2. The lowest dose of 75mg is the planned dose for further development. The data will now undergo further review so that Novartis and Molecular Partners can determine the appropriate next steps for the program.

05:18 EST Pluristem, Tnuva Group to establish cultured food platform - Pluristem (PSTI) and Tnuva Group announced the launch of a collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry. The collaboration started with the incorporation of a new company, or NewCo, that will receive exclusive, global, royalty bearing licensing rights to use Pluristem's proprietary technology, intellectual property and knowhow, to be used in the field of cultured meat. Tnuva Group will invest $7.5M in NewCo, according to a pre-money valuation of $40M, with the option to invest up to an additional $7.5M over a period of 12 months following the closing. NewCo will use its own funding and resources to promote its mission with a dedicated management team and staff, and Pluristem will support the establishment, research and development activities of NewCo pursuant to a services agreement. Tnuva will provide the R&D platform to develop consumer products and will receive preferred marketing rights of any developed NewCo's products in Israel. Pluristem has the industry-leading capacity to design, develop, and manufacture cells for commercial use. Over the last two decades, the company developed a proprietary three-dimensional expansion platform that can produce high-quality cells in a cost-effective manner with batch-to-batch consistency. According to both parties' estimates and plans, NewCo intends to present its technology Proof of Concept in 2022, with the goal of launching its first raw cultured meat product in 2023. As part of the collaboration, the Parties may expand the collaboration to include cultured dairy and cultured fish products by establishing separate, new ventures.

05:12 EST InterDigital, Sony Corporation of America extend pact and renew patent license - InterDigital (IDCC) announced an extension of its business partnership and renewal of its patent license with Sony Corporation of America (SONY). As well as renewing Sony's license to InterDigital's patent portfolio, the companies agreed to extend the term of the Convida Wireless joint venture, which has helped them deepen their research in areas such as 5G and the Internet of Things.